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Aspartylglucosaminuria (AGU) is an 
inherited lysosomal storage disease. 
Deficiency of enzyme called glycosy-
lasparaginase results in an accumu-
lation of glycopeptides in cells lead-
ing to a multisystem disease. There 
is no disease-specific treatment for 
AGU. In this study, a treatment ap-
proach called enzyme replacement 
therapy (ERT) was applied to AGU. 
The results reveal disease-specific 
details involved in ERT of AGU and 
form a basis for further development 
of treatment protocols.
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ABSTRACT 
 
Aspartylglycosaminuria (AGU) is a recessively inherited lysosomal storage disease caused 
by the deficient activity of lysosomal enzyme, glycosylasparaginase (AGA). The enzyme 
normally functions in lysosomes in degradation of carbohydrate-protein linkage in 
glycoproteins. The deficient AGA activity leads to the accumulation of glycoasparagines, 
mainly aspartylglucosamine (GlcNAc-Asn), in cells resulting in this multisystem disease 
characterized by slowly progressing psychomotor retardation with shortened life span. 
There is no disease-specific treatment for AGU, but some other lysosomal storage disorders 
with similar cause have been treated with enzyme replacement therapy (ERT) using 
exogenous recombinant enzymes. In this study the applicability of ERT was evaluated in 
the treatment of AGU. Therefore, a human recombinant glycosylasparaginase was 
produced and the mechanism of enzyme transfer and capability of an exogenous enzyme 
to treat AGU in a cell culture and in a mouse model were studied. 
The human recombinant AGA was transported from cell culture media into the AGU 
fibroblasts and lymphocytes through mannose 6-phosphate (M6P) receptor-mediated 
endocytosis. The GlcNAc-Asn storage in AGU lymphocytes was cleared and further 
accumulation was prevented when intracellular glycosylasparaginase activity in these cells 
reached 3-4% of the activity in normal lymphocytes. Cell-to-cell contact was needed for the 
M6P-receptor independent transfer of the enzyme from normal to AGU cells. The 
recombinant enzyme was biologically active also in the AGU mouse model. The lysosomal 
storage was cleared in many somatic tissues of adult AGU mice when 70% of normal 
glycosylasparaginase activity was reached in these tissues. The response to the therapy was 
dose-dependent. The recombinant enzyme crossed blood-brain barrier (BBB) of adult AGU 
mice and decrease in GlcNac-Asn storage was detected also in brain. The overall 
therapeutic effect in new-born animals was similar to the effect in the adult animals, but the 
therapeutic effect in brain was better when the therapy was initiated before the full 
development of the BBB. 
This study sheds light on details involved in ERT of AGU. The results show that ERT 
might be efficient in treating the somatic tissues of AGU, but more efficient ways to treat 
the disease in neuronal tissues are needed. The results form a basis for further development 
of treatment protocols in AGU, but also contribute to research in other diseases with similar 
cause. 
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TIIVISTELMÄ 
 
Aspartyyliglykosamiiniuria (AGU-tauti) on peittyvästi periytyvä aineenvaihduntasairaus, 
joka johtuu glykosyyliasparaginaasi -entsyymin (AGA) aktiivisuuden puutoksesta. 
Normaalisti entsyymi toimii lysosomeissa glykoproteiinien hajotuksessa pilkkoen 
proteiinin ja sokeriketjun välisen sidoksen. Aktiivisen entsyymin puuttuessa elimistön 
soluihin kertyy hajoamattomia glykoasparagiineja, pääasiassa aspartyyliglukosamiinia 
(GlcNAc-Asn). Tämä johtaa taudin kliinisiin oireisiin, joita ovat mm. hitaasti etenevä 
psykomotorinen jälkeenjääneisyys ja lyhentynyt elinikä. AGU-tautiin ei ole spesifistä 
hoitoa, mutta samankaltaisia lysosomaalisia kertymäsairauksia on hoidettu 
entsyymikorvaushoidolla (ERT) käyttäen rekombinanttia entsyymiä. Tässä työssä arvioitiin 
ERT:n soveltuvuutta AGU-taudin hoitoon tuottamalla ihmisen rekombinanttia 
glykosyyliasparaginaasia, tutkimalla mekanismia, joilla entsyymi siirtyy solusta soluun 
sekä tutkimalla tuotetun entsyymin kykyä hoitaa AGU tauti soluviljelmässä ja taudin 
hiirimallissa. 
Soluviljelymediumiin lisätty ihmisen rekombinantti AGA otettiin sisään 
lymfosyytteihin ja fibroblasteihin mannoosi 6-fosfaatti (M6P) –reseptorivälitteisellä 
endosytoosilla. Kertymätuote (GlcNAc-Asn) hävisi lymfosyyteistä ja sen lisäkertyminen 
estyi, kun entsyymiaktiivisuus tautisolun sisällä oli 3-4 % normaalin solun 
entsyymiaktiivisuudesta. Entsyymi siirtyi terveestä solusta sairaaseen solu-solu-kontaktissa 
ilman M6P-reseptorivälitteistä kuljetusmekanismia. Tuotettu entsyymi oli biologisesti 
aktiivinen myös AGU-taudin hiirimallissa. Lysosomaalinen kertymä hävisi monessa AGU-
tautia sairastavan aikuisen hiiren somaattisessa kudoksessa, kun entsyymiaktiivisuus 
kudoksessa oli 70 % normaalista aktiivisuudesta. Hoidon teho riippui annetusta 
annoksesta. Rekombinantti entsyymi läpäisi aikuisen AGU-hiiren veri-aivoesteen ja 
kertymä pieneni aivokudoksessa. Vastasyntyneellä AGU-hiirellä hoidon kokonaisteho oli 
samankaltainen kuin aikuisilla hiirillä, mutta teho aivoissa oli parempi, kun hoito aloitettiin 
ennen veri-aivoesteen täydellistä kehittymistä. 
Tämän tutkimuksen tulokset antavat lisätietoa entsyymikorvaushoidon soveltamisesta 
AGU-taudin hoitoon. Tulokset osoittavat, että ERT voisi olla mahdollinen somaattisten 
kudosten hoitomuoto, mutta hermokudoksen hoitamiseen tarvitaan tehokkaampia keinoja. 
Tulokset luovat pohjaa AGU-taudin hoitomuotojen kehittämiselle ja sen lisäksi täydentävät 
muiden samakaltaisten tautien parissa tehtyä tutkimusta. 
 
Luokitus: QU 136, QU 350, QU 55, QY 60.R6, WD 205 
 
Yleinen suomalainen asiasanasto (YSA): entsyymit, koe-eläimet, lysosomaalinen kertymäsairaus, 
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 1 Introduction 
 
Lysosomes are cellular compartments in the endosomal-lysosomal system where the 
degradation of macromolecules of the human body occurs (Walkley 1998; Vellodi 2005). 
They contain numerous enzymes which in cascade degrade endocytosed or phagocytosed 
molecules into smaller components for re-use or elimination (Vellodi 2005; Winchester 2005). 
In lysosomal storage disorders (LSD), the degradation is disturbed due mainly to the 
defective action of a particular lysosomal enzyme or a transport protein. The deficient 
enzyme activity is usually caused by an inherited genetic defect in a single gene coding the 
enzyme, leading to the accumulation of undigested storage material in the lysosomes, which 
results in a disease (Reuser et al. 1994; Futerman and van Meer 2004; Vellodi 2005). However, 
the exact pathogenesis and mechanisms behind the cellular dysfunction in these diseases are 
currently not known. The large phenotypic heterogeneity of LSDs is explained by the nature 
of the enzyme defect, the accumulating substrate and the target tissues of the storage. Some 
of the diseases are restricted to somatic tissues, whereas some also affect the brain. Over 40 
disorders have been described since the first identified LSD, Pompe disease in 1963 (Hers 
1963), and they are classified on the basis of the affected lysosomal function or the main 
accumulating substrate (Table 1) (Reuser et al. 1994; Wilcox 2004; Vellodi 2005). 
Glycoproteinoses, also called olicosaccharidoses, are lysosomal storage disorders where 
the stepwise degradation of glycoproteins (Figure 1) is disturbed, leading to the 
accumulation of different glycopeptides (Aronson 1999; Winchester 2005). 
Aspartylglycosaminuria (AGU, McKusick 208400) is a glycoproteinose where a deficiency of 
an enzyme called glycosylasparaginase (aspartylglucosaminidase, GA, AGA) leads to the 
accumulation of glycoasparagines, mainly aspartylglucosamine (GlcNAc-Asn), in tissues and 
body fluids (Jenner and Pollit 1967; Mononen and Mononen 1997; Winchester 2005). The 
accumulation starts already in the fetus, but the first sign of the disease is usually delayed 
speech development, which is detected in early childhood. The constant accumulation of the 
undegraded glycopeptides finally leads to a multisystem disease with a wide range of 
symptoms characterized by a slowly progressive psychomotor retardation and coarsening of 
the habitus (Arvio et al. 1997; Aula et al. 2001). Patients affected by AGU have a shortened 
  
2 
life span, typically not more than 40-50 years. Currently, there is no cure for AGU or any 
other glycoproteinose. 
The possible strategies to treat the lysosomal storage disorders have been widely 
studied. In addition to non-specific treatment of the symptoms, the object is to find disease-
specific therapies addressing the biochemical cause of the diseases. Here, the replacement of 
the malfunctioning enzyme with a correctly functioning one appears as a natural choice, as 
most of these disorders result from the malfunction of a single enzyme in the degradation 
cascade (Winchester et al. 2000; Vellodi 2005). The possible strategies could be the 
replacement of the deficient enzyme with an endogenous one produced in the patient’s body 
either after bone marrow transplantation (BMT), cell transplantation or gene therapy, or the 
replacement by an exogenous enzyme injected into the body (enzyme replacement therapy, 
ERT). Bone marrow and cell transplantations have been carried out in many LSDs, but the 
host versus craft reaction in bone marrow transplantations and the failure to affect the 
skeletal and central nervous system have stalled the use of these applications (Malatack et al. 
2003). However, a successful transplantation provides for a continuous supply of the 
correctly functioning enzyme and might therefore be helpful in the early stage of the disease 
prior to other therapies. The continuous supply of the enzyme might also be achieved by 
gene therapy, but the lack of safe vectors providing for the stable expression of the enzyme 
has thus far been the major obstacle for utilizing this approach (Sands and Davidson 2006). 
Currently, safer and more stable viral and non-viral vectors with different injection routes 
are being developed, and there is considerable interest in this therapeutic appreach (Sands 
and Davidson 2006; Zhang et al. 2008). Moreover, during the past few years stem cell 
research has been extensive and stem cells might provide a continuous source of endogenous 
enzyme in ERT of LSD in the future. 
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Table 1. Lysosomal storage disorders. 
Disease Enzyme deficiency Storage products 
Mucopolysaccharidoses (MPS)   
I Hurler/Scheie -L-Iduronidase Heparan sulfate, dermatan sulfate 
II Hunter Iduronidase sulfatase Heparan sulfate, dermatan sulfate 
IIIA Sanfilippo A Heparan N-sulfamidase Heparan sulfate 
IIIB Sanfilippo B -N-acetylglucosaminidase Heparan sulfate 
IIIC Sanfilippo C Acetyl-CoA:alpha-glucosamide Heparan sulfate 
IIID Sanfilippo D N-acetylglucosamine 6-sulfatase Heparan sulfate 
IVA Morquio A Galactose 6-sulfatase Keratan sulfate 
IVB Morquio B -Galactosidase Keratan sulfate, chondroitin sulfate 
VI Maroteaux-Lamy N-Acetylgalactosamine-4-sulfatase Dermatan sulfate 
VII Sly -Glucuronidase Dermatan sulfate, heparan sulfate, keratan sulfate  
Glycoproteinoses   
Aspartylglycosaminuria Glycosylasparaginase Glycoasparagines 
-Fucosidosis -Fucosidase Fucosyl-oligosaccharides/-glycolipids 
-Mannosidosis -Mannosidase -Mannosyl-oligosaccharides 
-Mannosidosis -Mannosidase -Mannosyl-oligosaccharides 
Sialidosis (Mucolipidosis I) -Neuraminidase Sialylololigosaccharides/gangliosides 
Schindler disease -N-acetylgalactosaminidase Oligosaccharides/glycosaminoglycans/glycosphingo-
lipids 
Sphingolipidoses   
Fabry disease 
 
-Galactosidase Globotriaosyl-digalactosylceramide/blood group B 
Trisaccharide 
Farber disease (lipogranulomatosis) Ceramidase Ceramide 
Gaucher disease Glucocerebrosidase Glucosylceramide 
GM1 gangliosidosis -Galactosidase GM1 ganglioside/galactosyloligosacharides/keratan 
sulfate 
Tay-Sachs disease (GM2 -Subunit of -hexosaminidase GM2 ganglioside/asialo-GM2 
Sandhoff disease -Subunit of -hexosaminidase GM2 ganglioside/asialo-GM2/globoside 
Globoid cell leukodystrohpy Galactosylceramidase Galactosylceramide, galactosylsphingosine 
 (Krabbe disease)   
Metachromatic leukodystrophy Arylsulfatase A Sulfatides 
Niemann-Pick A and B Sphingomyelinase Sphingomyelin 
Other lipidoses   
Neuronal ceroid lipofuscinosis ? ATP synthase 
Niemann-Pick C ?  Cholesterol, phospholipids, glycolipids 
Wolman disease (choresteryl-ester-
storage disease) 
Acid lipase Choresterylesters, triglyserides 
Glycogen storage disease   
Glycogen storage disease type II -Glucosidase Glycogen 
 (Pompe disease)   
Multiple enzyme deficiency   
Galactosialidosis Cathepsin A/protective protein Sialyloligosaccharides 
I-Cell disease (pseudo-Hurler 
polydystrohpy) 
UDP-N-acetylglucosamine:lysosomal 
enzyme N-Acetyl-glucosaminyl-1-? 
Oligosaccharides/lipids/glycosaminoglycans 
Mucolipidosis II/III   
Mucolipidoses IV ? Gangliosides, phospholipids 
Multiple sulphatase deficiency Various sulfatases Sulfated glycosaminoglycans/sulfated glycolipids 
Lysosomal transport defects   
Cystinosis Cystine transporter Cystine 
Salla Disease (sialic acid storage) Sialic acid/acid sugar transporter Sialic acid 
Vitamin B12 transport defect B12 transport system Cobalamin 
Activator deficiencies   
Complex lipidosis Prosaposin (Glucosyl)ceramide, sulfatides, ceramide 
Gaucher variant SAP C (Glucosyl)ceramide 
Metachromatic leukodystrophy SAP B Sulfatides/digalactosylceramide/globotriaosylceramide 
Tay-Sachs AB variant GM2 activator deficiency GM2 ganglioside 
Other   
Dannon disease   
Hyaluronidase deficiency   
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           I-IV: Protein-Carbohydrate linkage region    1-5:Carbohydrate 
   
  I:  Catepsins 
  II:  α-L-Fucosidase 
  III: Glycosylasparaginase 
  IV: Chitobioase 
 
  1: α-Neuraminidase 
  2: β-D-Galactosidase 
  3: N-Acetyl- β-D-Hexosaminidase 
  4: α-D-Mannosidase 
  5: β-D- Mannosidase 
 
Figure 1. The bidirectional pathway of degradation of human complex type N-linked glycoprotein (Aronson 
1999; Winchester 2005). Enzymes I-IV degrade the protein-carbohydrate linkage region with simultaneous 
degradation of the carbohydrate by enzymes 1-5. Specific glycoproteinoses are caused by a defect in these 
proteolytic enzymes as seen in Table 1.  = fucose; ■ = N-acetylglucosamine;  = mannose;  = galactose; 
 = N-acetylneuraminic acid. 
 
ERT in the treatment of lysosomal storage disorders has been the focus of much research 
since the 1970s, when it was found that a lysosomal enzyme was transferred from the cell 
culture media to certain cells by mannose 6-phosphate (M6P) receptor-mediated endocytosis 
(Kaplan et al. 1977). Thereafter, the nature of N-linked glycoproteins, which many lysosomal 
enzymes are, and the receptor-mediated transfer of proteins into lysosomes have been under 
active research, creating a basis for the development of ERT for lysosomal storage disorders 
(Kornfeld 1990; Hawkes and Kar 2004; Helenius and Aebi 2004; Hebert et al. 2005; Ohtsubo 
and Marth 2006). As a result, the disease- specific factors in Gaucher, Fabry and Pompe 
diseases and in MPS I, MPS II, and MPS VI with no central nervous system involvement 
have been characterized in adequate animal models, and ERT is in clinical use in these 
diseases (Brady 2006; Lidove et al. 2007; Harmatz et al. 2008; Katzin and Amato 2008; Wraith 
2008). Once begun, the ERT lasts for a life-time and the exogenous enzyme is injected 
regularly into the body. Therefore, recombinant proteins with a suitable targeting signal 
have been developed for the therapy, to overcome the problem of the shortage of naturally 
occurring enzyme and to achieve the maximal targeting of the enzyme to the affected cell 
type. The succesfull treatment of these diseases by ERT has boosted hope for the 
development of ERT in other lysosomal storage diseases as well. However, the transfer of 
enzyme through the blood-brain-barrier (BBB) in diseases that affect the brain needs to be 
efficient to ameliorate the involvement in central nervous system. 
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When this Ph.D. thesis project was started in 1993, no results had been reported on 
therapeutic approaches in AGU or in any other disorder of glycoprotein degradation (Table 
2). The enzyme defect behind the disease was known and the enzyme had been 
characterized. The main accumulating compounds had also been identified and methods to 
measure the enzyme activity as well as the accumulating compounds had been developed. 
The disease was quite well characterized clinically and it could be diagnosed, but only 
supportive medical care was avaliable. By that time, many studies on the treatment of other 
lysosomal storage diseases had been published. Therefore, in the continuum of research on 
AGU it appeared natural to aim towards disease-specific therapy. Thus, encouraged by the 
results obtained especially in Gaucher disease (Barton et al. 1991), we developed a 
recombinant glycosylasparaginase and further explored the mechanism of AGA transfer and 
the applicability of ERT in the treatment of AGU in cell culture and in a mouse model. This 
thesis outlines these studies, summarizes the data and applies it to the current knowledge of 
AGU and to the research in the treatment of lysosomal storage disorders in general. 
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Table 2. Milestones related to aspartylglycosaminuria research from patients’, families’ and clinicians’ point of view when 
the present study was started. The data were collected from the studies referred to in Chapter 2 (Review of literature). 
 
 Milestones in research related to AGU AGU patient and family Clinician 
1962 - The first diagnostic picture of an AGU patient is 
drawn.  
- No knowledge of the reason for the 
abnormal state and mental retardation of 
the child. 
- Diagnosis cannot be made 
and the patient cannot be 
helped. 
1965-
1967 
- GlcNAc-Asn linkage is characterized. 
- AGA and the reaction mechanism of the 
enzyme are discovered. 
- AGA is found to be a lysyomal enzyme. 
 - Hint that new findings 
may be related to mental 
retardation in some 
patients. 
1968 - AGU is discovered; missing AGA activity and 
GlcNAc-Asn in urine is related. 
- The disease is named and information 
about the causes is given, but otherwise 
families cannot be helped. 
- AGU disease can be 
diagnosed and named, but 
patients and families 
cannot be helped 
otherwise. 
1970-
1975 
- A high prevalence of AGU is found in Finland. 
- The clinical picture, mode of inheritance and 
epidemiology of AGU are established. 
- Morphological and histochemical characteristics 
are established. 
- Diagnostic method using urinary GlcNAc-Asn is 
developed. 
- Families can get information about the 
clinical outcome and can plan the future of 
the AGU child. 
- The AGU child can get better supportive 
care, which can be planned and organized. 
- AGU can be more easily 
suspected and detected. 
- Speculative genetic 
counseling as well as 
plans and instructions for 
supportive care can be 
given.  
1976 - AGA is purified from human liver. 
- AGU patients and carriers can be diagnosed 
using blood AGA activity. 
- Possible anxiety in relatives of an AGU 
patient when planning a family may occur. 
- Genetic counseling can be 
given. 
1984-
1989 
- Automated HPLC and GLC methods to detect 
GlcNAc-Asn are developed. 
- Prenatal diagnosis (AGA activity) from chronic 
villus samples, cultured amniotic cells or 
amniotic fluid is established. 
- Subunit composition of AGA is found. 
- Prenatal diagnosis is available. 
- Parents are allowed to terminate the 
pregnancy, which can also cause a lot of 
distress and mixed feelings.  
- As AGU can be detected 
more easily than before 
and the information of the 
status of the fetus can be 
given more rapidly, the 
role of genetic counseling 
becomes more important. 
1990-
1992 
- cDNA for AGA is cloned: one gene, two 
subunits. 
- AGUFin mutations and AGA gene is 
characterized. 
- Human leukocyte AGA is characterized. 
- Series of studies on the activation of AGA are 
initiated 
- DNA-based detection of AGU or AGU mutation 
(carrier) is available 
- Chromosomal location of AGA gene is 
established. 
- Gene test is available. 
- Families and children can be tested and 
knowledge of carrier status can be 
obtained.  
- An area of difficult decisions is opened. 
- AGU and carrier status 
can be diagnosed by gene 
tests. 
- Informing the families 
becomes more important 
and may be difficult. 
1993-
1994 
- Automated HPLC methods to detect AGA is 
developed. 
- The diagnosis can be reached faster than 
earlier.  
- Different choices for 
laboratory testing are 
available to make the 
diagnosis. 
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2 Review of literature 
 
 
2.1 ASPARTYLGLUCOSAMINURIA 
 
Aspartylglycosaminuria (AGU; MIM 208400) is a recessively inherited lysosomal storage 
disease due to a deficiency in glycoprotein degradation (Mononen and Mononen 1997; Aula 
et al. 2001). It is the most common disorder in glycoprotein degradation in humans 
(Mononen et al. 1993a). AGU is part of the Finnish disease heritage, with an estimated 
prevalence from 1:3600 to 1:18500, thus being the most common lysosomal and the fifth most 
common recessively inherited disease in the Finnish population (Mononen et al. 1991; Arvio 
et al. 1997; Norio 2003). In Finland there are over 200 AGU patients, compared with 
approximately 30 patients reported in the rest of the world (Norio 2003). 
 
2.1.1 Discovery of AGU 
AGU was discovered in England in the late 1960s through the detecting of an unknown 
polar compound in the urine of a 31-year-old mentally retarded woman (Pollit 1997). The 
compound was defined as an amino acid asparagine attached to N-Acetylglucosamine 
(AADG; 2-acetamido-1[-L-’-aspartamido]- 1,2-dideoxyglucose; aspartylglucosamine; 
GlcNAc-Asn) (Jenner and Pollit 1967). The lack of a previously identified enzyme cleaving 
the asparagine-carbohydrate linkage (Murakami and Eylar 1965; Makino et al. 1966), later 
called glycosylasparaginase (AGA, GA), was now connected to AGU disease (Pollit et al. 
1968). The enzyme was not found in the seminal fluid of AGU patients, while secretion of 
GlcNAc-Asn was detected (Murakami and Eylar 1965; Makino et al. 1966; Pollit et al. 1968). 
At the same time, AGU was also identified in Finland: a previously unknown glycopeptide 
was found in the urine of eleven mentally retarded Finnish patients (Palo and Mattsson 1970; 
Palo 1997). A new disease had been found and extensive research on its pathophysiology 
started. 
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2.1.2 Molecular biology behind the disease 
The lack of the glycosylasparaginase activity leading to the secretion of glycopeptides into 
tissues and body fluids of an AGU patient is due to the recessively inherited mutations in the 
gene coding for this enzyme (Murakami and Eylar 1965; Makino et al. 1966; Ikonen et al. 
1991; Mononen et al. 1991; Aula et al. 2001). Altogether 98% of Finnish AGU patients carry 
the so-called AGUFIN major mutation, consisting of two point mutations in the AGA gene 
(Fisher and Aronson 1991; Ikonen et al. 1991; Mononen et al. 1991; Syvanen et al. 1992). 
These mutations result in two amino acid substitutions in the polypeptide chain of the 
protein, Arg161Gln and Cys163Ser. The first substitution is a neutral polymorphism but the 
second one is responsible for the misfolding of the protein, leading to the inactivation of the 
enzyme. This mutation is termed a founder mutation in the Finnish population. The AGUFIN 
minor mutation is a 2-bp deletion which creates a frameshift and premature translational 
termination codon, and is found in 1.5% of Finnish AGU patients (Isoniemi et al. 1995; Aula 
et al. 2001). In addition to these so-called Finnish mutations, 25 other mutations causing the 
disease have been found, including missense, splicing and nonsense mutations as well as 
insertions, deletions and genomic rearrangements (Park and Aronson 1997; Aronson 1999; 
Aula et al. 2001). Almost all of them lead to incorrect maturation and complete or partial 
inactivation of the enzyme. 
 
2.1.3 Lysosomal storage in AGU 
An inactive glycosylasparaginase cannot hydrolyze the protein-oligosaccharide linkage, 
which is the final step in the lysosomal catabolism of Asn-linked glycoproteins (Figure 1) 
(Aronson 1999). These undigested glycoasparagines are subsequently secreted into body 
fluids and accumulate in lysosomal vacuoles in the tissues (Arstila et al. 1972; Isenberg and 
Sharp 1976; Rapola 1994; Aula et al. 2001). The lysosomal storage in turn causes 
morphological changes in the cells, such as enlarged lysosomes filled with amorphous 
granular material which can be seen in histological studies. In the neuronal cells of the adult 
brain, these storage vacuoles contain electron-dense granular bodies, as shown by histology 
and magnetic resonance imaging (MRI) (Arstila et al. 1972; Haltia et al. 1975). The cellular 
vacuoles in some tissues also seem to include lipid droplets. The exact content of the storage 
vacuoles is difficult to detect by staining methods, probably because of the small size of the 
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storage compounds and their high solubility in water and solvents, and it is therefore poorly 
characterized (Mononen and Mononen 1997; Aula et al. 2001;). In contrast to somatic tissues, 
where lysosomal storage has been detected already during fetal life in several organs and cell 
types, fetal brain tissue has been found to be minimally affected (Aula et al. 1984b). 
Although our knowledge of the gene defects underlying the AGU has expanded and is 
currently quite good, the exact pathogenesis of the disease is not known. In various 
lysosomal storage disorders it is currently thought that the accumulation of storage material 
may lead to the specific disease by enlargement of the organs and by secondary biochemical 
and structural events (Mononen and Mononen 1997; Vellodi 2005). These secondary events 
might include deregulation of apoptosis due to the disturbed lysosomal function with 
altered inflammatory response (Wada et al. 2000; Tardy et al. 2004; Wu et al. 2005) or 
cytokine release followed by macrophage activation (Vellodi 2005), and most likely occur in 
AGU as well. 
 
2.1.3.1 Aspartylglucosamine 
In AGU, the main accumulating compound is aspartylglucosamine (GlcNAc-Asn; 2-
acetamido-1-(L--aspartamido)-1,2-dideoxy--D-glucose; N-acetylglucosaminyl-asparagine; 
AADG; GlcNAc-Asn) (Figure 2)(Maury 1980; Mononen and Mononen 1997; Aula et al. 2001). 
It is practically absent in tissues of healthy individuals, but it has been identified in many 
organs of adult AGU patients, including the liver, spleen and thyroid gland, kidneys, skeletal 
muscle, spinal cord, sciatic nerve, lymphocytes and brain tissue (Maury 1980; Maury and 
Palo 1980a; Maury and Palo 1980b; Maury et al. 1981). GlcNAc-Asn is also secreted into the 
body fluids and urine of AGU patients at concentrations many hundred-fold those in healthy 
individuals or heterozygous carriers with only trace amounts of storage material detected in 
their urine (Kaartinen and Mononen 1989). However, the urinary concentration of GlcNAc-
Asn is not linked to the severity of the disease (Aula et al. 1980). 
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Figure 2. The structure of an aspartylglucosamine (GlcNAc-Asn). 
*The hydroxyl group (OH) is replaced by a specific carbohydrate 
moiety in higher order glycoasparagines. 
 
2.1.3.2. Other accumulating glycoasparagines 
In all accumulating substrates in AGU, L-asparagine is attached to the N-acetylglucosamine 
(Figure 2). Various amounts of higher order glycoasparagines with different carbohydrate 
moieties including mannose, fucose, sialic acid and galactose attached to the N-
acetylglucosamine (marked with * in Figure 2) are also found in the urine and tissues of AGU 
patients (Maury 1980; Mononen and Mononen 1997; Aula et al. 2001; Kelo et al. 2005). These 
have been concluded to be partial degradation products of N-linked oligosaccharides. 
 
2.1.4 Clinical manifestations of AGU 
In spite of the accumulation of GlcNAc-Asn, the development of a fetus with AGU usually 
proceeds normally and the newborn shows no signs of the disease (Arvio et al. 1993; Arvio et 
al. 1997; Arvio and Arvio 2002). In Finland, AGU is diagnosed on average at the age of 5.5 
years, when delayed speech development together with concentration difficulties, with 
clumsiness and restlessness in some patients, attract attention. Most children with AGU also 
have recurrent respiratory infections. The nature of the disease is progressive and the 
developmental lifespan of the patients has been divided into three phases (Arvio and Arvio 
2002). During the first phase, from childhood up to the age of 15, AGU children learn new 
skills although their development is delayed. The skills peak at the age of 13-16 years, but the 
children are mildly mentally retarded and their developmental age corresponds to that of 
healthy 5-6–year-old children. In the second phase, from puberty up to the age of 25-28 
years, the patients are in a stable phase but they may lose some skills. Finally, in the third 
*OH 
OH
CH2OH 
O
HN 
  O 
NH2 
   HNAc 
COOH 
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phase, a rapid mental and physical retardation occurs, leading to death at approximately the 
age of 35-45 years. Patients with AGU carrying a non-Finnish mutations have similar 
phenotypic outcome as patients with the Finnish mutations (Aula et al. 2001). 
Thus, progressive mental retardation is the most characteristic feature of AGU. Adult 
patients may also be stubborn and aggressive when disturbed, and females in particular may 
also have psychotic periods of varying lengths. Additional findings in adult AGU patients 
include epileptic seizures, coarse facial features with puffy eyelids, thick eyebrows, round 
nostrils, skeletal changes, skin abnormalities, hepatospelenomegaly and joint disease (Arvio 
et al. 1997; Arvio et al. 2002; Arvio et al. 2004). Moreover, alterations on T2- and T1-weighted 
MRI images have recently been related to AGU (Autti et al. 2008). In addition, carriers of 
AGU with the mutation only in one allele, resulting in 50% of the normal AGA activity, may 
have a slightly altered facial appearance (Arvio et al. 2004) and a risk of developing chronic 
arthritis (Arvio et al. 2002). 
 
2.1.5 Biochemical diagnosis of AGU 
When a child is suspected of having AGU, the exact diagnosis can be made via quantitative 
determination of GlcNAc-Asn in urine or leukocytes by liquid chromatography (Mononen et 
al. 1986; Kaartinen and Mononen 1989; Kaartinen and Mononen 1990b). These HPLC 
methods can be automated and are thus feasible in clinical laboratories. Other methods for 
the determination of GlcNAc-Asn from urine include thin-layer chromatography (Humbel 
and Collart 1975; Sewell 1979), gas-liquid chromatography (Maury 1979) or an enzymatic 
treatment of GlcNAc-Asn (Sugahara et al. 1976). 
Since the AGA activity in the tissues or urine of an AGU patient is less than 5% of that in 
a healthy person (Mononen and Mononen 1997), reliable detection of the AGU can also be 
made by measuring the AGA activity in the urine, leukocytes, plasma, serum or cultured 
fibroblasts of the patient. The lack of enzyme activity can be detected by colorimetric 
(Makino et al. 1966; Aula et al. 1976) or fluorometric methods (Mononen et al. 1993b; Voznyi 
et al. 1993; Mononen et al. 1994), or by liquid chromatography (Kaartinen and Mononen 
1990a). 
For prenatal diagnosis of AGU, the practically absent AGA activity detected in cultured 
amniotic fluid cells can be used (Aula et al. 1984b; Mononen et al. 1988b; Aula et al. 1989). 
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However, due to the low fetal excretion of GlcNAc-Asn into the amniotic fluid, diagnosis 
based on the measurement of the storage material from the amniotic fluid is not reliable for 
prenatal diagnosis (Mononen et al. 1988a). 
Today, diagnosis and carrier detection of AGU can be achieved by DNA analysis if the 
specific mutation in the AGA gene causing the disease is known, which often is the case in 
Finland (Mononen et al. 1991; Syvanen et al. 1992; Delahunty et al. 1995). However, the cost 
of DNA analyses is high: in carrier screening performed in 1995-1996, the cost of detecting 
one adult AGU carrier was $434 (€334), which would result in a theoretical cost of $107,632 
(€82,790) to detect one affected fetus among 2912 screened pregnancies (Kallinen et al. 2001). 
Nevertheless, when the study was done, the attitudes of the parents tested and their close 
relatives towards genetic testing were positive (Hietala et al. 1995). 
 
 
2.2 HUMAN GLYCOSYLASPARAGINASE 
 
In the 1960s, the carbohydrate-to-protein linkage containing asparagine and N-
acetylglucosamine was precisely characterized (Yamashina et al. 1965) and 
glycosylasparaginase (N4-(-N-acetyl-glucosaminyl)-L-asparagine aminohydrolase; 
asparagine-N-acetylglucosamine; aspartylglucosaminidase; AGA; GA; EC 3.5.1.26) was 
discovered, when it was found that sweet-almond emulsion and sheep epididymis extract 
played a role in the degradation of this linkage region in glycoproteins (Lee et al. 1964; 
Murakami and Eylar 1965). It was also found that the same enzyme extracted from a guinea 
pig serum was an aminidase and not a glycosidase as was initially thought (Makino et al. 
1966). The enzyme was also soon connected to the AGU disease, as mentioned in Chapter 2.1 
(Discovery of AGU) (Jenner and Pollit 1967). In humans, the enzyme was first purified from 
the liver (Savolainen 1976). It has been found that the biochemical properties of the enzymes 
varies slightly from species to species (Noronkoski et al. 1997b), and this literature review 
concentrates on the human enzyme. 
To date, several names describing the enzyme’s action in the catabolism of glycoproteins 
have been used (Noronkoski et al. 1997b). The name glycosylasparaginase was eventually 
introduced to differentiate the enzyme from the -N-acetylglucosaminidases, which are 
endoglycosidases cleaving the N-acetylglucosaminyl moiety from the carbohydrates 
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(Tarentino et al. 1975) and to address the similarity of its reaction mechanism to that of L-
asparaginase (Kaartinen et al. 1992). The enzyme has been found to have aminase activity 
and the name glycosylasparaginase/-aspartyltransferase has also been proposed, but is not 
yet used (Noronkoski et al. 1998). 
 
2.2.1 Synthesis and protein structure of AGA 
Glycosylasparaginase is synthesized in the endoplasmic reticulum (ER) as a single inactive 
346-amino-acid-long precursor protein with two N-glycosylation sites and 9 cysteine 
residues (Fisher et al. 1990; Ikonen et al. 1991; Mononen et al. 1991; Mononen et al. 1992; 
Oinonen et al. 1995). The gene encoding AGA is localized on a long arm of chromosome 4 
(region q32-q33) (Aula et al. 1984a; Morris et al. 1992). 
The precursor protein of the active enzyme goes through several post-translational 
processing steps in the ER, starting with the removal of a 23-amino-acid N-terminal signal 
peptide. A properly folded precursor protein is then autocatalytically cleaved between the 
amino acids Asp205 (corresponding to the Asp182, if the 23-amino-acid signal peptide is not 
included in the numbering) and Thr206 (Thr183) into two subunits (pro- and pro-) (Fisher 
et al. 1990; Kaartinen et al. 1992; Ikonen et al. 1993; Riikonen et al. 1996; Guan et al. 1996; 
Saarela et al. 1998). These subunits are held together by non-covalent forces and are 
subsequently associated into a heterotetramer (22) structure which forms an active enzyme 
(Fisher et al. 1990; Kaartinen et al. 1991; Oinonen et al. 1995). Although the enzyme is a 
heterotetramer in the active form, it has also been postulated to exist as a heterodimer in 
solutions (Wang and Guo 2003).  
The active precursor enzyme is next transported into the lysosomes, where the 
processing proceeds by the cleavage of short sequences from the C-terminal ends of both 
subunits (Mononen et al. 1991; Tollersrud and Aronson 1992; Ikonen et al. 1993). This 
trimming has no effect on the catalytic activity of the enzyme. Instead, the critical 
posttranslational processing steps affecting the proper function of AGA include the 
formation of disulfide bridges between eight out of nine cysteine residues in the protein. 
These four intramolecular disulfide bridges between Cys64/Cys69 and Cys163/Cys179 in the 
-subunit and Cys285/Cys306 and Cys317/Cys345 in the -subunit are crucial for the 
stabilization, correct folding and subunit processing, and thus for the activation of the 
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enzyme (Enomaa et al. 1992; McCormack et al. 1995; Oinonen et al. 1995; Park et al. 1996; 
Riikonen et al. 1996). The AGUFIN, mutation prevents the formation of one of the disulphide 
bridges due to the substitution of the cysteine 163 by serine, which leads to the inactivation 
of the enzyme. 
Another important step in the posttranslational processing of the active AGA in the 
lysosomes is the attachment of carbohydrate chains to the glycosylation sites located in the 
- and -subunits. One glycosylation site in both -subunits is located in Asn38, and one in 
Asn308 in both -subunits. These four glycosylation sites in the the mature heterotetrameric 
enzyme contain both complex and high-mannose type oligosaccharide chains (Kaartinen et 
al. 1991). The glycosylation does not affect the folding or the processing of the enzyme, but 
the phosphorylation of these oligosaccharides is important for the stability of the enzyme 
inside the cells, and for the normal transport of the AGA from the ER into the lysosomes. The 
importance of the phosphorylation for the correct trafficking of the AGA indicates that the 
enzyme utilizes the mannose 6-reseptor mediated pathway in the transport process into 
lysosomes (Tikkanen et al. 1995; Park et al. 1996; Tikkanen et al. 1997). 
As a result of the activation process of the AGA, the sizes of subunits in the fully 
processed enzyme are 19-25 kDa for the heavy () subunit and 16-19 kDa for the light () 
subunit (Baumann et al. 1989; Halila et al. 1991; Kaartinen 1991; Kaartinen et al. 1991; 
Enomaa et al. 1992; Rip et al. 1992; Tollersrud et al. 1994). The small heterogeneity in the 
reported molecular masses probably results from the heterogeneity of the attached 
carbohydrate chains in enzymes purified from different sources, and from the diversity in 
the purification procedures of the enzyme and in the determination of the molecular weights 
in different studies. 
AGA is widely expressed in human tissues, but the highest activities are found in 
leukocytes and the strongest immunoreactivity in hepatocytes, renal tubule cells of kidneys 
and in pyramidal cells of the cerebral cortex (Enomaa et al. 1993). Immunostained AGA is 
also present in the Purkinje cells, in the soma and extensions of other neurons, and in the 
myelinated fibers in infant brains (Uusitalo et al. 1999). 
 
  
15 
2.2.2 Chemical properties of AGA 
The glycosylasparaginase in the human liver (Savolainen 1976; Dugal and Stromme 1977; 
McGovern et al. 1983; Baumann et al. 1989; Tollersrud and Aronson 1992), leukocytes 
(Kaartinen et al. 1991), urine (Kaartinen 1991) and chorionic villus cells (Kaartinen and 
Mononen 1990a) has similar chemical properties, having a broad pH optimum at pH 6-9. 
Although the enzyme is located in acidic lysosomes, the neutral or alkaline pH optimum 
suggests that the AGA could also have some function outside the lysosomes. The isoeletric 
point (pI) of the enzyme varies slightly, being at pH 5.7 for liver enzyme (McGovern et al. 
1983; Baumann et al. 1989; Enomaa et al. 1992;), pH 4.6-5.2 for leukocyte enzyme (Baumann 
et al. 1989; Kaartinen et al. 1991; Enomaa et al. 1992) and pH 4.9-5.0 for urinary enzyme 
(Baumann et al. 1989; Kaartinen 1991; Enomaa et al. 1992), indicating the charge 
heterogeneity of the enzymes purified from different sources. The enzyme is also very heat 
stable, remaining active in temperatures up to 60 oC (Baumann et al. 1989; Kaartinen et al. 
1991; Enomaa et al. 1992). 
 
2.2.3 Substrates, reaction mechanism and inhibitors of AGA 
The natural substrates of the enzyme include aspartylglucosamine (GlcNAc-Asn) (Makino et 
al. 1966) and larger glycoasparagines (Kaartinen et al. 1992; Risley et al. 2001; Kelo et al. 
2005). A prerequisite for the hydrolysis of these glycoasparagines is the existence of a free -
amino group in the substrate, which anchors it to the binding site of the enzyme, and -
carboxyl groups, which are crucial for the action of the enzyme in the asparagine moiety of 
the substrate (Lee et al. 1964; Kaartinen et al. 1991; Kaartinen et al. 1992; Risley et al. 2001; 
Kelo et al. 2005). Furthermore, a L-fucose attached to the N-acetylglucosamine prevents the 
action of glycosylasparaginase, indicating that the -fucosidase acts prior to AGA in the 
degradation of glycoproteins (Noronkoski and Mononen 1997). 
In the hydrolysis of L-Asparagine and N-Acetylglucosamine in the protein-
carbohydrate-linkage in glycoproteins, the aspartic acid (Asp) and 1-amino-N-
acetylglucosamine (GlcNAc-Asn-NH2) are formed through the -aspartyl enzyme 
intermediate. GlcNAc-Asn-NH2 is further non-enzymatically hydrolyzed into N-
acetylglucosamine (GlcNAc) and ammonia (NH3) (Makino et al. 1966; Kaartinen et al. 1992;). 
The Michaelis constant (Km) for the reaction varies from 0.09 to 1.25 mM for leukocyte, liver 
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or urinary AGA (Dugal and Stromme 1977; McGovern et al. 1983; Baumann et al. 1989; 
Kaartinen 1991; Kaartinen et al. 1991; Enomaa et al. 1992). 
Precise reaction mechanism of AGA has been reavealed by using crystal structures and 
functional analyses of the enzyme (Brannigan et al. 1995; Oinonen et al. 1995; Tikkanen et al. 
1996). According to these studies, AGA uses the same catalytic mechanism as the enzymes in 
the enzyme class termed N-terminal nucleophile (Ntn) hydrolases. The requirements for this 
mechanism include the existence of a free -amino group in the N-terminal residue of the 
substrate that is situated at the active site of the enzyme, and the existence of catalytic groups 
in the substrate binding pocket of the enzyme that act as a proton donor. In addition, the 
polar side-chain of the N-terminal amino acid residue is used as a nucleophile during the 
substrate hydrolysis. In AGA, a funnel-shaped active site is situated in a deep pocket 
between the -heterodimers ( sandwich core structure), where Thr206 is the N-
terminal residue in the -chain acting as a base, enhancing the nucleophility of the hydroxyl 
group of its own side chain (Kaartinen et al. 1991; Fisher et al. 1993). In the high pH optimum 
(pH 7-9) of the enzyme, significant amounts of -amino groups of Thr206 are uncharged and 
are thus able to act as a base in the acidic environment of the lysosomes. The amino acids 
Thr257 and Gly258 in the active site form an oxyanion hole which stabilizes the transition 
state of the enzyme-substrate complex (Oinonen et al. 1995; Riikonen et al. 1995; Tikkanen et 
al. 1996). The asparagine moiety of a substrate binds to the active site amino acids Arg234, 
Asp237, Thr257 and Gly258 mainly by hydrogen-bonding (Oinonen et al. 1995; Riikonen et 
al. 1995; Tikkanen et al. 1996). By serving as a binding site for the substrate, these amino 
acids stabilize the correct conformation of the active site and modify the properties of 
Thr206, leading to the breakage of an amine bond. Recently, Wang and Guo have proposed 
in the model of Flavobacterium meningosepticum that in addition to serving as a base in the 
activation of a nucleophile, Thr206 serves as an acid in the polarization of the leaving group 
during the catalytic process (Wang and Guo 2007). The authors also postulate that no water 
is included in the catalytic process. Instead, the complex is shielded from water and the free 
-amino group of Thr206 and its own side chain nucleophile are hydrogen-bonded to the 
sidechain hydroxyl group of Thr224, mediating the polarization process necessary for the 
activation. Based on this precise reaction mechanism and on the data of the autocatalytic 
activation process of AGA, it has been proposed that it belongs to the Ntn hydrolases 
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(Brannigan et al. 1995; Oinonen and Rouvinen 2000; Qian et al. 2003; Wang and Guo 2003; 
Saarela et al. 2004). 
In addition to the glycoasparagines, AGA is also capable of hydrolyzing -aspartyl 
peptides and derivatives as well as L-asparagine (Kaartinen et al. 1992; Mononen et al. 1993a; 
Noronkoski et al. 1997a; Noronkoski et al. 1998), thus demonstrating that 
glycosylasparaginase does not need carbohydrate in its substrates and may play a role in the 
metabolism of -aspartyl peptides. 
The 5-diazo-4-oxo-L-norvaline (DONV) is a specific inhibitor to AGA, abolishing the 
activity by irreversible binding to Thr206 in the active site of the enzyme (Kaartinen et al. 
1991). 
 
 
2.3 TREATMENT OF LYSOSOMAL STORAGE DISEASES 
 
The main goal in the treatment of lysosomal storage diseases is to decrease or eliminate 
substrate accumulation in order to prevent symptoms of the disease. The choice of treatment 
strategy is disease-specific and is based on the pathophysiology and severity of the disease, 
on the target organ and on the availability of tools and techniques for carrying out the 
therapy (Winchester et al. 2000; Treacy and others 2001; Wenger et al. 2003). One treatment 
strategy might be diminishing the substrate accumulation by restricting the lysosomal 
substrate flow or by dispersing the accumulated substrate by substrate deprivation therapy. 
Furthermore, the residual enzyme activity found in some diseases can be enhanced, and this, 
in turn, results in diminished accumulation of the substrate. When the disease is caused by 
one malfunctioning enzyme, a feasible approach is to replace this enzyme either by direct 
administration of an exogenous enzyme or by creating an endogenous enzyme pool by 
transplanting cells or genes into a body or a specific tissue. Today, these different treatment 
strategies are being intensively researched in animal models (Winchester et al. 2000; Haskins 
et al. 2002; Suzuki et al. 2003; Wenger et al. 2003; Zhu et al. 2006). However, to date only 
bone marrow and stem cell transplantation (BMT), which creates an endogenous enzyme 
pool, enzyme replacement (ERT) by exogenous enzyme administration, and substrate 
reduction therapy are in clinical use in in some LSDs (Beck 2010). However, there is no 
curative treatment for the diseases with symptoms in the central nervous system. 
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2.3.1 Enzyme replacement therapy 
The term enzyme replacement therapy (ERT) is commonly used for a therapeutic approach 
where the malfunctioning enzyme is replaced and thus the lysosomal storage is corrected by 
direct injection of an exogenous enzyme into a patient. Usually, the enzyme is injected into 
the blood stream. The prerequisite for ERT is the availability of a sufficient quantity of stable, 
safe and non-immunogenic exogenous enzyme, which is correctly transported from an 
extracellular environment into the lysosomes of the cells. Moreover, the enzyme has to be 
biologically active, i.e. capable of degrading the lysosomal storage and prohibiting further 
accumulation of the substrate once it has reached the target cells. Beyond this, many disease-
specific factors such as optimal dosage and injection intervals and the pharmacologic effects 
of the enzyme need to be clarified for the successful treatment of a specific disease. To fulfill 
these requirements, the nature and function of the enzyme inside the cells and 
pathophysiological events in the disease need to be characterized. 
To date, ERT with exogenous enzymes has been approved for clinical use in the non-
neurological variant of Gaucher disease ( Barton et al. 1991; Grabowski et al. 1995; Davies et 
al. 2007), Fabry disease (Eng et al. 2001; Schiffmann et al. 2001; Lidove et al. 2007; Morel and 
Clarke 2009), MPS I (Kakkis et al. 1994; Wraith et al. 2004; Lidove et al. 2007; Sifuentes et al. 
2007), MPS II (Wraith et al. 2008), MPS VI (Anson et al. 1992; Harmatz et al. 2008), and 
Pompe disease (Katzin and Amato 2008; Strothotte et al. 2010) (Table 3). None of these 
diseases involve serious neurological symptoms which need to be treated. In addition, ERT 
has been studied in animal models, in addition to AGU, in MPS VII (Vogler et al. 1993), GM1 
gangliosidosis (Samoylova et al. 2008), MPS IIIA (Bielicki et al. 1998; Urayama et al. 2008), 
MPS IIIB (Yu et al. 2000), Nieman-Pick disease (Miranda et al. 2000), -mannosidosis (Roces 
et al. 2004; Crawley et al. 2006; Samoylova et al. 2008;), metachromatic leukodystrophy 
(Matzner et al. 2005), sialidosis (Wang et al. 2005), and Krabbe disease (Lee et al. 2005) (Table 
3). Most of these diseases affect the central nervous system. 
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Table 3. Lysosomal storage disorders in which ERT has been studied (excluding AGU). 
Disease CNS 
involvement 
Recombinant 
enzyme a) 
Animal 
model 
In 
clinical 
use 
References  
Mucopolysaccharidoses      
MPS I  X X X Kakkis et al, 1994; Wraith et al, 2004; 
Lidove et al, 2007; Sifuentes et al, 2007 
MPS II  X X X Muenzer et al, 2002, Muenzer et al, 2006, 
Wraith, 2008 
MPS IIIA X X X  Bielicki et al, 1998; Urayama et al, 2008 
MPS IIIB X X X  Yu et al, 2000 
MPS VI  X X X Anson et al, 1992; Harmatz et al, 2008 
MPS VII X X X  Vogler et al, 1993 
Glycoproteinoses      
-Fucosidosis X X   Bielicki et al, 2000 
-Mannosidosis X X X  Berg et al, 2001; Roces et al, 2004; Crawley 
et al, 2006; Samoylova et al, 2008 
Sialidosis X X (murine) X  Wang et al, 2005 
Sphingolipidoses      
Fabry disease 
 X 
X X 
Ioannou et al, 1995; Eng et al, 2001; 
Schiffmann et al, 2001; Lidove et al, 2007; 
Morel & Clarke, 2009 
Gaucher disease X
 b) X X X c) Barton et al, 1991; Grabowski et al, 1995; 
Davies et al, 2007; 
GM1 gangliosidosis X X (feline) X  Samoylova et al, 2008 
Tay-Sachs disease X X   Akeboshi et al, 2007 
Sandhoff disease X X   Akeboshi et al, 2007 
Krabbe disease X X (murine)   Lee et al, 2005 
Metachromatic leukodystrophy X X X  Matzner et al, 2005 
Niemann-Pick A and B X X X  Miranda et al, 2000; He et al, 1999 
Other lipidoses      
Neuronal ceroid lipofuscinosis 
(Batten) 
X X   Lin & Lobel, 2001 
Glycogen storage disease      
Pompe disease   X X X 
van Hove et al, 1996; Bijoet et al, 1998, 
Bijvoet et al, 1999; Katzin & Amato, 2008; 
Strothotte et al, 2010 
a) Human recombinant enzyme unless otherwise stated, b) In neuronopathic variant, c) In non-neuronopathic variant 
 
2.3.1.1 Receptor-mediated endocytosis of exogenous enzymes 
In ERT, an exogenous enzyme injected into the patient is transported and targeted to cells 
and lysosomes by the lysosomal/endosomal system. Although in some cell types a newly 
synthesized lysosomal enzyme can be sorted by a non-receptor mediated transfer, the 
soluble enzyme protein injected into the extracellular environment of the patient is mainly 
targeted by receptor-mediated endocytosis (Kornfeld and Mellman 1989; Dittmer et al. 1999; 
Grabowski and Hopkin 2003; Vellodi 2005;). The key factor in correct targeting is that the 
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enzyme bears an appropriate signal which is recognized by the receptor in the desired cell 
type. These targeting signals include mannose/N-acetylglucosamine, recognized by 
monocytes and macrophages, sialic acid, recognized by glial cells, asialogalactose, 
recognized by hepatocytes, fucose, recognized by fibroblasts, and mannose 6-phosphate 
(M6P), recognized by most of the cell types, including brain cells ( Bou-Gharios et al. 1993a; 
Dittmer et al. 1999; Sly 2000; Grabowski and Hopkin 2003; Urayama et al. 2004; Sleat et al. 
2005; Vellodi 2005; Beck 2007). 
The M6P receptor, which is the most abundant, has been investigated extensively. 
Indeed, two receptors belonging to the P-type lecitin family have been identified (Dahms 
and Hancock 2002; Ghosh et al. 2003). They are termed the cation-dependent (CD-MPR) and 
the cation independent (CI-MPR) M6P receptors. The latter are also called cation-
independent insulin-like growth factor II/MPR receptors (IGF-II/MPR), based on their ability 
to bind IGF-II in the cell surface, and thus playing a role also in other important 
physiological processes such as fetal development and apoptosis (Ghosh et al. 2003; Hawkes 
and Kar 2004). Although both of these receptors function in the sorting and trafficking of the 
newly synthesized lysosomal enzymes, they have distinct functions in vivo (Pohlmann et al. 
1995; Sohar et al. 1998; Schellens et al. 2003). Importantly, only CI-MPR is capable of binding 
soluble extracellular lysosomal enzymes which have M6P recognition markers ( Stein et al. 
1987; Dahms and Hancock 2002; Olson et al 2004;). Interestingly, the M6P recognition marker 
has also been identified in a set of lysosomal enzymes found in the brain, and the receptor 
has been demonstrated to mediate the transport of lysosomal enzyme across the blood-brain 
barrier (Urayama et al. 2004; Sleat et al. 2005; Urayama et al. 2008). 
In receptor-mediated targeting, attention should be paid to whether the enzyme is 
delivered and distributed correctly also in the diseased state. It may not be enough that the 
enzyme has an appropriate targeting signal, since the longlasting lysosomal storage may 
disturb the endosomal/lysosomal system and the cellular uptake of exogenous enzymes 
(Dhami and Schuchman 2004; Keslová-Veseliková et al. 2008; Ohashi et al. 2008). 
 
2.3.1.2 Recombinant enzymes 
When the concept of ERT was introduced in the 1970s (Brot et al. 1974), one limiting step was 
the availability of pathogen-free corrective enzyme in the large quantities needed for the 
therapy. However, the development of DNA techniques in the 1990s enabled the mass-
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production of the recombinant human enzymes by expressing them in bacterial or animal 
cells. The prerequisites in the production are the stable expression of the recombinant protein 
and the correct post-translational processing, stability and safety of the produced enzyme 
preparate, none of which can be taken for granted. Although the recombinant enzymes can 
be quite easily and cheaply produced in insect cells or in yeast, to date mammal cells have 
been preferred as an expression system due to their ability to carry out the complex post-
translational processing steps of the recombinant protein, in a similar way to natural 
processes (Chen et al. 2000a; Chen et al. 2000b; Du et al. 2001; Bonten et al. 2004; Akeboshi et 
al. 2007). In addition, the recombinant enzymes produced in mammalian cells have a glycan 
structure similar to the natural ones, making them less immunogenic when introduced into a 
mammalian body. 
The use of recombinant enzymes for therapeutic purposes gives an opportunity to 
modify the oligosaccharide targeting signals of these enzymes in a controlled way (Kornfeld 
and Mellman 1989; Ginsel and Fransen 1991; Sands et al. 2001; Dhami and Schuchman 2004; 
Du et al. 2005; Zhu et al. 2005). By this means, the therapeutic effect can be enhanced and 
made more wide compared with those of natural enzymes. Indeed, during the last decade, 
the modified glucocerebrosidase has been used in the treatment of non-neuronopathic 
Gaucher disease, although the advantage of modification in this enzyme preparation has 
lately been questioned (Grabowski et al. 1995; Van Patten et al. 2007). 
To date, many different recombinant human lysosomal enzymes in addition to AGA 
have been produced (Table 4). Only a few of them are in clinical use, the majority being used 
only in exploring the possibilities of ERT (Table 3). Among these enzymes is a recombinant -
N-acetylglucosaminidase produced for the treatment of MPS IIIB, which turned out be of 
limited value due to deficient mannose 6-phosphorylation, resulting in incomplete targeting 
and uptake of the enzyme in the affected cells, which emphasizes the importance of the 
correct posttranslational processing of the recombinant enzymes (Zhao and Neufeld 2000; 
Weber et al. 2001). In addition to the production of human enzymes, a feline -galactosidase 
has been produced to study ERT in a feline model of GM1 (Samoylova et al. 2008), and a 
murine sulfaminidase, neuraminidase (Neu1) and galactosylceramidase to study ERT in 
mouse models of MPS IIIA, sialidosis and Krabbe disease, respectively (Gliddon and 
Hopwood 2004; Lee et al. 2005; Wang et al. 2005). 
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Table 4. The human recombinant enzymes produced for ERT (excuding AGA). 
Disease Recombinant enzyme References  
Mucopolysaccharidoses   
MPS I -L-Iduronidase Kakkis et al, 1994 
MPS II Iduronate-2-sulphatase Muenzer et al, 2002; Muenzer et al, 2006; Wraith, 
2008 
MPS IIIA Sulphamidase Bielicki et al, 1998 
MPS IIIB -N-Acetylglucosaminidase Yu et al, 2000 
MPS VI Arylsulphatase B Anson et al, 1992 
MPS VII -Glucuronidase Vogler et al, 1993 
Glycoproteinoses   
-Fucosidosis a-L-Fucosidase Bielicki et al, 2000 
-Mannosidosis -Mannosidase Berg et al, 2001 
Sphingolipidoses   
Fabry disease -Galactosidase A Ioannou et al, 1992 
Gaucher disease Glucocerebrosidase Barton et al, 1991; Grabowski et al, 1995; Davies 
et al, 2007 
Tay-Sachs disease -Hexosaminidase A Akeboshi et al, 2007 
Sandhoff disease -Hexosaminidase A Akeboshi et al, 2007 
Metachromatic leukodystrophy Arylsulphatase A Matzner et al, 2005 
Niemann-Pick A and B Acidic sphingomyelinase He et al, 1999; Miranda et al, 2000 
Other lipidoses   
Neuronal ceroid lipofuscinosis (Batten) Neuronal 2 protein (CNL2p) Lin & Lobel, 2001 
Glycogen storage disease   
Pompe disease  Acid -glucosidase Van Hove et al, 1996; Bijvoet et al, 1998; Bijvoet 
et al 1999 
 
2.3.1.3 Enzyme dosage 
In every clinically approved ERT, there are recommendations for the dosage and the 
injection intervals. However, these recommendations are not necessarily optimal for every 
patient, or even for every organ or for the different tissues of the patient. For example, a low 
amount of enzyme may cure some symptoms, and changing the dose in the course of the 
therapy may sometimes be beneficial (Garcia et al. 2007; Wilson et al. 2007; de Fost et al. 
2008). Furthermore, although a sufficient amount of the enzyme should always exist in the 
body to prevent the accumulation of the substrate, increasing the dose into 
supraphysiological amounts can be harmful for the function of the cell and will not benefit 
the therapy. In other words, the enzyme dose should be optimal for the function of the cell 
and the lysosome, and the current scientific view emphasizes the fact that for an optimal 
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therapy, the enzyme dose should also be individualized (Hollak et al. 1995; Pastores et al. 
2004; Andersson et al. 2005). This raises the need for knowledge of the pathophysiology of 
the disease, the stage of the disease in the individual patient and detailed knowledge of the 
enzyme preparation that is used. 
 
2.3.1.5 ERT and the brain 
The major limitation and future challenge in ERT is the targeting of the exogenous enzymes 
to the brain. The enzyme replacement therapies that are now in clinical use do not affect the 
CNS involvement of the disease. The challenge is to get the corrective enzyme to traverse the 
blood-brain barrier (BBB) and thereby achieve the therapeutic effect also in the brain. 
The development of the BBB has been shown to occur gradually and the full tightening 
is achieved if not during the fetal development then during the first few days or weeks after 
birth (Stewart and Hayakawa 1987; Rubin and Staddon 1999; Engelhardt 2003). The solutes 
of the blood cannot passively diffuse across the fully developed barrier, but there are various 
transport mechanisms for e.g. macromolecules (Begley 2003). In particular, it was recently 
discovered that the recombinant human -glucuronidase and sulfaminidase were able to 
cross the BBB in newborn mice via MPR/IGFII receptor-mediated endocytosis (Urayama et 
al. 2004; Urayama et al. 2008). Furthermore, this active transport capacity was lost in adult 
animals, suggesting that in addition to the BBB, the transport mechanisms are also 
developmentally downregulated. However, it has also been shown that following 
intravenous injection of the enzyme, some recombinant enzymes can be transported into the 
adult brain by some so far unclear mechanisms (Lee et al. 2005; Matzner et al. 2005; Vogler et 
al. 2005; Crawley et al. 2006). Interestingly, it has been shown that the elimination of the 
mannose 6-phosphate and mannose residues in recombinant -glucuronidase dramatically 
enhance the delivery of this enzyme cross the adult mouse BBB and consequently the 
correction of lysosomal storage in brain (Grubb et al. 2008). In addition, a less 
phosphorylated -mannosidase has been shown to pass the BBB of adult -mannosidosis 
mice further proposing an alternative delivery system different from the M6P mediated 
endocytosis for therapeutic enzyme to enter to adult brain (Blanz et al. 2008). 
One way to overcome the BBB is to inject the enzyme straight into the cerebrospinal 
fluid (CSF) by intrathecal injection (Kakkis et al. 2004), or into the brain by intrastriatal 
(Lonser et al. 2005) or intraventricular injection (Chang et al. 2008). Importantly, in all of 
  
24 
these studies, the recombinant enzymes were distributed into different areas of the brain 
where they were able to diminish the lysosomal storage. This indicates that the different cells 
in the brain are not rigid but are capable of internalizing the exogenous enzyme and of 
correcting the lysosomal storage in vivo. However, in the efficient treatment of the disease 
requiring life-lasting repeated injections, this might not be a suitable approach. 
 
2.3.2 Bone marrow or stem cell transplantation 
Bone marrow transplantation (BMT) or the transplantation of cord blood, fetal liver or brain- 
derived stem cells is a therapeutic approach in which a constant supply of endogenous 
corrective enzyme is created by transplanted donor cells (Olsen et al. 1988; Krivit et al. 1992; 
Malatack et al. 2003; Wenger et al. 2003; Vellodi 2005; Givogri et al. 2006; Martin et al. 2006; 
Ringden et al. 2006; Terskikh et al. 2006; Malm et al. 2008). Therefore, these are also referred 
to as endogenous enzyme replacement therapies. BMT or hematopoetic stem cell 
transplantation (HCT) are currently clinically available in more than 20 lysosomal storage 
disorders. The best results have been obtained in individuals with mild soft-tissue 
involvement or in cases where the therapy has been started before the symptoms arise. 
Bone marrow or stem cell transplantation arose from the realization that many 
mammalian tissues can self-renew and differentiate throughout life. Indeed, it has been 
found that stem cells, e.g. hematopoetic stem cells (HSC) of the bone marrow or fetal liver, 
mesenchymal stormal cells (MSC) of the bone marrow or neural stem cells (NSC) of the brain 
are capable of differentiating into many types of cells depending on the origin of the cells 
and the microenvironment of the transplant (Bjorklund and Svendsen 1999; Kim et al. 2004; 
Nakano et al. 2001; Simard and Rivest 2004; Terskikh et al. 2006; Pelagiadis et al. 2008). The 
donor-derived normal cells produce the missing enzyme, which is then transferred into the 
surrounding cells, where it clears the accumulation of the substrate. In somatic tissues, the 
transfer of the enzyme has been shown to occur directly in cell-to-cell contact from the 
normal to the diseased cells or by a receptor-mediated endocytosis after the enzyme has been 
released from normal cells into the circulation (Olsen et al. 1981; Olsen et al. 1983; Bou-
Gharios et al. 1993b; Olsen et al. 1993; Wilcox 2004). The direct transfer is restricted to certain 
soluble enzymes, but when it occurs it has been been demonstrated to induce the synthesis 
of new lysosomal enzyme precursors (Olsen et al. 1988). 
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Although the renewal of bone or CNS by stem cell therapy is more limited, a restraining 
of the neurocognitive decline has been shown in humans after BMT (Krivit et al. 1999; 
Simard and Rivest 2004) or HCT (Olsen et al. 1988; Grewal et al. 2004; Malm et al. 2008;). In 
addition, the neuronal stem cells or progenitor cells have been shown to cross the BBB and to 
generate neurons and microglia and also to decrease the lysosomal storage in the brain in 
animal models (Snyder et al. 1995; Bjorklund and Svendsen 1999; Shihabuddin et al. 2004). 
Stem cells have also been shown to cross the BBB in humans, even though the engraftment of 
microglia after bone marrow transplantation is a very slow process (Simard and Rivest 2004; 
Vellodi 2005). 
The drawbacks of BMT are high mortality and morbidity and difficulties in finding an 
HLA-matching donor. On the other hand, it is suggested that by using HLA-matched 
unrelated donor stem cells or mesenchymal stormal cells in the transplantation, 
immunological reactions and the graft-versus-host rejection could be avoided (Pelagiadis et 
al. 2008). In addition, partially HLA-matched unrelated donor cord blood has been used with 
good outcome when a suitable bone marrow donor cannot be found (Martin et al. 2006). But 
before establishing the clinical value of stem cells or neural progenitor cells, many 
transplantation-related issues need to be solved. These include how to expand the stem cell 
amount in vitro and what is the optimal administration route. Transplantation is also 
currently a high risk procedure and might not be suitable for a newborn child. 
 
2.3.3 Gene therapy 
Gene therapy of lysosomal storage diseases caused by the defect of a single gene involves 
introducing a gene of a malfunctioning protein into the body or tissue where it is then 
expressed, generating a long-term pool of a normally functioning corrective protein (Verma 
and Weitzman 2005; O'Connor and Crystal 2006). Preclinical experiments of gene therapy in 
animal models of more than 25 LSDs have been reviewed recently (Ellinwood et al. 2004; 
Sands and Davidson 2006; Geel et al. 2007; Sevin et al. 2007a) and reported by several 
authors (Cardone et al. 2006; McIntyre et al. 2008; Ramsubir et al. 2008). 
To accomplish gene transfer, the gene has to be introduced into the recipient genome for 
expression. This can be achieved by attaching the gene to a vector capable of transferring the 
gene. To date, the most commonly used vectors in studies with LSDs are RNA or DNA viral 
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vectors, including retro- and lentiviruses and adeno- and adeno-associated viruses 
(Ellinwood et al. 2004; Sands and Davidson 2006). In addition to these viral vectors, non-viral 
vectors have recently been studied and are already used in cancer treatment, for example 
(Nishikawa et al. 2008). In LSDs, the non-viral vectors that have been most researched 
include a plasmid DNA with or without chemical capsulation (Hodges and Cheng 2006; 
Nishikawa et al. 2008; Zhang et al. 2008), and most recently a plasmid DNA encapsulated in 
Trojan horse liposomes (Schlachetzki et al. 2004; Zhang et al. 2008). 
The gene transfer can be attained in vivo or ex vivo (Sands and Davidson 2006). In in vivo 
transfer the gene is introduced into the body by an intravenous injection (Cardone et al. 2006; 
Traas et al. 2007; Herati et al. 2008; McIntyre et al. 2008; Tessitore et al. 2008) or by injecting it 
into a specific organ (Geel et al. 2007; Tessitore et al. 2008). Although the therapeutic enzyme 
itself or the vector with the corrective gene has been shown to cross the BBB and to evoke a 
therapeutic effect at least to a certain extent, site-directed injection of the gene product has 
been used to enhance the therapeutic effect of the transfer in the brain (Eto et al. 2004; 
Schlachetzki et al. 2004; Sands and Davidson 2006; Broekman et al. 2007; Cearley and Wolfe 
2007; Chung et al. 2007; Liu et al. 2007; Sevin et al. 2007b; Sands and Haskins 2008). In 
addition, a neonatal injection into the brain has been investigated in this therapeutic 
approach as well (Ramsubir et al. 2008). In ex vivo therapy, the gene transfer and genetic 
altering is done in specific cells in vitro prior to the transplantation of these cells into the 
affected body (Sands and Davidson 2006). Ex vivo gene therapy has been performed by 
transplanting modified fibroblasts (Moullier et al. 1993), but currently the research has 
turned to transplanting genetically modified bone marrow or stem cells(Biffi et al. 2004; 
Enquist et al. 2006; Sands and Davidson 2006; Ramsubir et al. 2008). This approach of 
modifying multipotent cells has been shown to have potential for more efficient treatment 
than just modifying the already differentiated cells. 
Although the results obtained in the studies mentioned above are promising, larger 
animal models have been developed to better mimic the size of the human newborn (Casal 
and Haskins 2006; Zhang et al. 2008). In fact, in the late-infantile form of neuronal ceroid 
lipofuscinosis, a clinical trial using intracranial injection and recombinant AVV vector has 
already been started (Enns and Huhn 2008). However, there are still problems to overcome 
before this approach can be in wider use: stable expression of the gene in the transfected cell 
type is not guaranteed with current techniques, and safety issues including immunogenity 
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and tissue-specific expression of the vectors needs to be addressed in detail (Sands and 
Davidson 2006). In addition, prior to widely used clinical applications, targeted integration 
techniques have to be studied and developed to prevent unwanted events such as leukemia 
(Kohn et al. 2003; Ramsubir et al. 2007). In the distant future, novel strategies such as the 
substitution of an affected gene by a wild type one using targeted restriction endonucleases 
and homologous recombination might also be available for lysosomal storage disorders with 
a single gene defect. 
 
2.3.4 Other therapeutic approaches 
In addition to creating an exogenous or endogenous enzyme pool for the correction of 
lysosomal storage, other strategies involve enzyme enhancement therapy and substrate 
reduction therapy. These so-called small-molecule therapies introduced in this chapter might 
be an option for the treatment either alone in certain diseases or in combination with other 
therapies. 
In enzyme enhancement therapy, also called chaperone therapy, the residual activity of 
the mutated enzyme is increased by small-molecular-weight ligands (Desnick 2004; Beck 
2007; Enns and Huhn 2008; Parenti 2009). These molecules, e.g. substrate analogues, active-
site inhibitors, enzyme cofactors or effector molecules, bind reversibly to the misfolded 
proteins, stabilizing or reshaping them, leading to correct targeting and thus functioning in 
the lysosomes. This therapy approach has been studied in animal models in Pompe disease, 
Gaucher disease, MPS I, GM1–gangliosidosis and Tay-Sachs disease (Desnick 2004; Geel et 
al. 2007; Sidransky et al. 2007; Enns and Huhn 2008). The one advantage of this approach is 
that these small molecules can cross the BBB, thus eliciting the therapeutic effect also in 
neuronal tissues. The studies have been promising, but because these molecules are 
mutation-specific their use is also disease or even individual specific. 
Substrate reduction therapy, also called substrate deprivation therapy, using an 
iminosugar inhibitor, is in clinical use in non-neurological Gaucher disease (Cox et al. 2003). 
A small inhibitor molecule reduces the biosynthesis of accumulating macromolecules, which 
in turn leads to a reduced toxic effect of the substrate in the lysosomes (Beck 2007). As in 
chaperone therapy, the small inhibitor molecules used in substrate deprivation therapy can 
cross the BBB and have been thought to be good candidates for treating the diseases with 
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CNS symptoms (Jakóbkiewicz-Banecka et al. 2007; Enns and Huhn 2008). The therapy has 
been shown to reduce the level of the substrate accumulating in the brain in Nieman-Pick 
disease type C (Patterson et al. 2007), and to have a possible anti-inflammatory effect in the 
brain of newborns affected by Tay-Sachs disease (Bembi et al. 2006). On the other hand, this 
therapeutic approach did not arrest the neurological deterioration related to these diseases. It 
might have a beneficial effect on neurological symptoms, when used in combination with 
some other therapy, as shown in Gaucher disease type III in combination with ERT (Capablo 
et al. 2007). However, more research is needed in this area. 
 
2.3.5 Application of therapeutic approaches to AGU 
Antibiotics, psychoactive drugs and surgery have been used as supportive medical care in 
AGU disease, but to date there is no cure for the disease (Arvio and Arvio 2002). Since AGU 
is caused by the lack of activity of one lysosomal enzyme, and there is no considerable 
amount of residual enzyme activity in the tissues of AGU patients, the approaches to 
consider for the treatment are enzyme-based therapies: ERT, bone marrow or cell 
transplantation, and gene therapy. These approaches have been studied in cell cultures, and 
the generation of mouse models mimicking human AGU disease has opened the possibilities 
for in vivo studies (Kaartinen et al. 1996; Jalanko et al. 1998; Kaartinen et al. 1998). Some 
patients have also been treated by bone marrow transplantation, but so far there is no 
recommendation for the disease-specific treatment in addition to supportive medical care. 
 
2.3.5.1 BMT or stem cell transplantation and gene therapy 
It has been shown that bone marrow transplantation in adult AGU mice corrects the tissue 
pathology in the liver and the spleen (Laine et al. 1999). Six months after the transplantation, 
3% of the normal enzyme activity was detected in the brain, but no effect on the lysosomal 
accumulation of the substrate was seen. When the transplantation was performed on 3-
week-old AGU mice, a clear reduction of vacuolization of neurons was detected eight and 
ten months after BMT, indicating the importance of early transplantation (Laine et al. 2004). 
To date, an allogenic BMT has been performed on seven AGU patients aged 1 to 10 years 
(Autti et al. 1997; Arvio et al. 2001; Malm et al. 2004). The BMT was shown to slowly 
normalize some pathological, biochemical and MRI findings or at least to halt the 
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progression of AGU-specific health problems, e.g. neurological deterioration in some 
transplanted AGU patients (Autti et al. 1999; Malm et al. 2004). Despite these results, it has 
been stated that the benefits of the transplantation are somewhat difficult to estimate due to 
a short follow-up time, and currently BMT is not recommended as a treatment at least after 
infancy (Arvio et al. 2001). Indeed, it has been suggested that the follow up should be 
extended to at least 10 years and the transplantation should be performed as early in life as 
possible (Malm et al. 2004; Ringden et al. 2006). 
Retrovirus-mediated gene transfer has been performed in vitro in human AGU 
fibroblasts and lymphocytes as well as in mouse neuroblastoma and rat glioma cells 
(Enomaa et al. 1995). Gene transfer was successful in all of these cells, and in the AGU 
fibroblasts the AGA activity was nearly normalized. In addition, transduced AGU 
lymphocytes secreted AGA into cell culture medium and corrected the enzyme deficiency in 
AGU fibroblasts in co-culture. In vivo gene transfer has been performed in the AGU mouse 
using adenovirus vectors with either a sarcoma virus promoter or a tissue-specific non-viral 
promoter (Enomaa et al. 1995; Peltola et al. 1998; Virta et al. 2006). An expression of AGA 
was demonstrated in the liver after intravenous injection of gene product. Interestingly, 
when the transgene was injected intraventricularly or intrastriatally, diffusion of the AGA 
activity into neighboring cells was detected. The use of non-viral tissue-specific promoters 
lead to more stable expression than the use of a viral promoter, which emphasizes the 
significance of the choice of promoter (Peltola et al. 1998; Virta et al. 2006). These results may 
lead future research towards therapy of distinct cell types, which in turn may open new 
possibilities in the area of gene therapy. 
 
2.3. 5..2 Enzyme replacement therapy 
In addition to this study, enzyme replacement has been studied in vitro using a recombinant 
glycosylasparaginase purified or secreted from CHO cells (Enomaa et al. 1995; Kyttala et al. 
1998). In these studies, mouse primary fibroblasts and neural cells and rat glioma cells 
endocytosed the recombinant AGA. The internalization of the AGA was shown to be M6P 
dependent, though these cell lines were shown to express cation-independent M6P receptors 
(Kyttala et al. 1998). Also, tumor-derived mouse or rat neuronal cell lines internalize the 
AGA, but to a much lower extent (Kyttala et al. 1998). Interestingly, these cell lines did not 
express CI-M6P receptors. The observation that glial cells have a better capacity than 
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neurons for uptaking AGA has been verified in later studies (Harkke et al. 2003). Although 
internalization of the enzyme was demonstrated by different cell types, the biological 
activity, i.e. the capability of endocytosed enzyme to degrade the accumulated substrate in 
the AGU cells, has not been shown. 
ERT with suitable recombinant enzyme might be benefical in AGU, but to confirm this 
further research is needed on the enzyme and its biological activity and on disease-related 
factors in the ERT of AGU. 
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3 Aims of the study 
 
 
When this study started, the mechanism of enzyme transfer and ERT as a treatment strategy 
for many mucopolysaccharidoses and mucolipidoses had been studied but no studies of the 
treatment of AGU had been published. 
 
The aims of the present work were: 
 
1. To produce a recombinant glycosylasparaginase and to characterize its biological 
activity in AGU cell culture. 
 
2. To study the mechanism of cell-to-cell transfer of glycosylasparaginase from normal to 
diseased cells in a cell culture model. 
 
3. To study the efficacy of recombinant glycosylasparaginase in the correction of 
aspartylglycosaminuria in a mouse model with different enzyme dosages and treatment 
schedules. 
 
4. To evaluate the effect of the early initiation of ERT in the AGU mouse model. 
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4 Materials and methods 
 
 
4.1 CHEMICALS AND REAGENTS 
 
All commercial chemicals and reagents used in the study were purchased from suppliers as 
described in the original papers (I-IV). The affinity-purified AGA antibodies from hen egg-
yolk were produced by immunization of hens with a synthetic peptide representing amino 
acids S(156)-R(169) of the human glycosylasparaginase (Mononen et al. 1991; Kokko and 
Karenlampi 1992). The rabbit immune serum was obtained by immunization of rabbits with 
the human glycosylasparaginase. 
 
 
4.2 HUMAN RECOMBINANT GLYCOSYLASPARAGINASE (I, III, IV) 
 
4.2.1 Expression and purification (I, III, IV) 
The cDNA for the coding region of the glycosylasparaginase was isolated as described 
elsewhere (Ikonen et al. 1991; Mononen et al. 1991). The 2.1 kb cDNA was isolated from the 
human placental cDNA library and inserted into a modified mammalian expression vector 
pCDX under the control of SV40 promoter sequences. The DNA from the pCDX-GA was 
transfected into NIH-3T3 mouse fibroblasts by the calcium phosphate precipitation method. 
DNA from pSV-2 was used in cotransfection to attain the neomycin (G418)-resistance for the 
selection of stable transformants. 
The recombinant human glycosylasparaginase was purified from NIH-3T3 fibroblasts 
based on the method described by Kaartinen and co-workers using DEAE-Sepharose and 
Mono-Q anion exchange columns, and gel filtration as a chromatographic purification steps 
(Kaartinen et al. 1991). The purity of the enzyme preparation was confirmed by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with 12 % gels in which 
proteins were localized by silver or Coomassie blue staining. Protein markers with known 
molecular weight were used to confirm the molecular weights of the protein subunits. 
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4.2.2 Endoglycosidase and phosphatase digestion (I) 
For endoglycosidase digestion, 10 mU of the recombinant glycosylasparaginase was 
incubated with 20 mU of endoglycosidase H in 100 mM citrate/phosphate buffer, pH 5.5 at 
37oC for 17 hours. Another 20 mU of endoglycosidase H was added and incubation was 
continued at 37oC for 17 hours more. Liberation of carbohydrates was confirmed by SDS-
PAGE using 12% gels, protein markers of known molecular weight and Coomassie blue 
staining. For dephosphorylation, 4.25 mU of the recombinant glycosylasparaginase was 
incubated with 1.4 U of Escherichia coli alkaline phosphatase in 260 l of 50 mM Tris-HCl 
buffer, pH 8.0 at 37oC for 3.5 hours. The glycosylasparaginase activity of the treated enzyme 
preparations was confirmed by fluorometric assay (4.8.1) after both treatment procedures. 
 
 
4.3 HUMAN LEUKOCYTE GLYCOSYLASPARAGINASE (II) 
 
The leukocyte glycosylasparaginase was purified from leukocytes isolated form human 
blood as described by Kaartinen and coworkers (Kaartinen et al. 1991). The purification 
procedure involved precipitation, gelfiltration and chromatographic steps, the last step being 
anion exchange chromatography on Mono-Q column. The purity and subunit composition of 
the enzyme preparation was studied on SDS-PAGE with 12% gel. The specific activity of the 
enzyme preparation was 96 mU/mg protein measured by fluorometric assay (4.8.1). 
 
 
4.4. CELL LINES (I, II) 
 
Epstein Barr virus (EBV) transformed B-cell lines were developed from peripheral blood 
lymphocytes obtained from a Finnish AGU patient carrying the AGUFIN-mutation 
(Cys163Ser) or from healthy persons by a method described by Volkman et al. (Volkman et 
al. 1984). The transformed cells were grown in RPMI medium supplemented with 10%-15% 
FCS. The AGU fibroblasts were obtained from a Finnish AGU patient carrying the AGUFIN-
mutation, and the normal fibroblasts were obtained from a healthy person. The fibroblasts 
were grown in DMED containing 10% fetal calf serum (FCS) or RPMI/15% FCS. 
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4.5. ANIMALS (III, IV) 
 
The AGU mouse model was generated through targeted disruption of a mouse 
glycosylasparaginase gene in embryonic stem cells as described elsewhere (Kaartinen et al. 
1996). The mice completely lacked glycosylasparaginase activity and accumulated the 
aspartylglucosamine in tissues and urine, resembling the clinical, biochemical and 
histochemical characteristics of the human disease (Kaartinen et al. 1996; Kaartinen et al. 
1998). The genotype of the mice were confirmed by southern blot analysis of the tail DNA 
samples (wild-type, WT: Aga+/+, heterozygous, HE: Aga+/-, homozygous, KO: Aga-/-). 
 
 
4.6 CELL CULTURE EXPERIMENTS (I, II) 
 
AGU fibroblasts or lymphocytes and normal fibroblasts or lymphocytes treated with the 
experimental protocols described below without enzyme addition were used as negative and 
positive controls, respectively, in the experiments described below. In these cell culture 
experiments, biochemical analyses of the cell homogenates included determination of the 
glycosylasparaginase activity by fluorometric assay (4.8.1) and the aspartylglucosamine 
concentration by the HPLC method (4.8.2), and determination of the protein concentration 
(4.8.3) unless otherwise stated. Prior to biochemical analyses the cells were washed two to six 
times with ice-cold PBS and lysed in 0.5 ml of 1% sodium deoxycholate in 50 mM Tris-HCl, 
pH 7.4 by freezing and thawing three times, followed by sonication and centrifugation. 
 
4.6.1 Endocytosis of recombinant glycosylasparaginase in fibroblasts and lymphocytes (I) 
To study the endosytosis of human recombinant AGA to EBV-transformed lymphocytes, 8 x 
107 cells grown in RPMI/10% FCS were rinsed twice with PBS and incubated in 6 ml of 
PBS/10% FCS containing recombinant glycosylasparaginase at concentrations of 0, 0.1, 1, 3, 
10, 30, 100 and 300 mU/l up to 14 days. 3 ml of cell suspension was withdrawn from the 
culture for biochemical analyses and 3 ml of fresh AGA containing PBS-FCS media was 
added.  
To study the effect of M6P or sugar residues of AGA in endosytosis, human AGU 
fibroblasts were grown to confluency in DMEM/10% FCS on 35 mm tissue culture dishes. 
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The cells were rinsed twice with 3 ml of PBS and incubated with 2 mU of endoglycosidase H 
or alkaline phosphatase-treated glycosylasparaginase or 2 mU of untreated 
glycosylasparaginase with mannose 6-phosphate addition at concentrations of 0.05 mM, 0.2 
mM, 0.5 mM, 2 mM and 4 mM in duplicates in 1 ml of PBS/10% FCS up to 3 hours. After the 
incubation, the cells were washed and lysed for biochemical analyses as described above. 
For immunofluorescence microscopy (4.8.5), 4.6 x 106 EBV-transformed lymphocytes 
grown in RPMI/10% FCS media were rinsed two times with PBS, after which they were 
cultured in 6 ml of media containing 100 mU of AGA/ml. 3 ml of cell suspension was 
replaced with fresh AGA- containing media after one day of culture. 1 ml of cell suspension 
was withdrawn from the culture for analysis on day 2. The cells were washed twice with PBS 
and suspended to the final concentration of 0.2 x 106 cells/ml of PBS for cytocentrifugation. 
 
4.6.2 Endocytosis of human leukocyte glycosylasparaginase in lymphocytes (II) 
To study the endosytosis of human leukocyte AGA to EBV-transformed lymphocytes, 5-6 x 
106 cells were cultured in 25 cm2 tissue culture flasks in 6 ml of RPMI/15% FCS up to 10 days 
in the presence of the leukocyte glycosylasparaginase at concentrations of 0, 0.1, 1, 3, 10, 30, 
100 and 300 mU/l. For biochemical analyses, 3-5 x 106 cells (3 ml) were withdrawn from the 
culture at each time point up to 14 days. 3 ml of fresh AGA-containing media was added to 
the culture. The cells were washed 2 times with PBS and lysed for biochemical analyses. 
For determination of the duration of the therapeutic effect, 25 x 106 EBV-transformed 
lymphocytes were cultured in the presence of 1000 mU/l of leukocyte AGA in 30 ml of 
RPMI/15% FCS medium for 9 hours, after which the cells were washed and the culture (5 x 
106 cells) was continued in a medium without AGA supplementation. For biochemical 
analyses, 5 x 106 cells (3 ml of medium) were withdrawn from the culture 2, 3, 6 and 9 hours 
and 1, 2, 4, 7, 10 and 13 days after the start of the experiment. Equal amounts of fresh 
medium were added at each time point. 
 
4.6.3 Co-cultivation of normal and AGU cells (II) 
To study the enzyme transfer in co-cultivation, a total of 10 x106 normal (female) and AGU 
(male) EBV-transformed lymphocytes were co-cultured in 80 cm2 tissue culture flasks in a 
mixture containing 20-100% of normal lymphocytes in 20 ml of RPMI/15%FCS up to 10 days. 
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5 ml of the cell suspension containing 2.5 to 10 x 106 cells was withdrawn for biochemical 
analyses, and another 5 ml for determination of the number of Y-chromosome-containing 
cells at each time point. For the biochemical analysis the cells were washed twice with PBS 
and lysed as described above. For in situ Y-chromosome hybridization assay (4.8.4) the cells 
were treated with colcemid solution and KCl, fixed with methanol-acetic acid solution and 
attached to ethanol-treated slides. 
To study the transfer of the enzyme without cell-to-cell contact, 2 x106 AGU lymphocytes 
and 2 x106 normal lymphocytes in 8 ml of RPMI/15% FCS medium were cultured up to 10 
days in a 6-well dish separated by 0.4 m semi-permeable polycarbonate membrane (Nunc) 
to prevent cell-to-cell contact. During the culture 1-4 x106 cells in 2 ml of medium from both 
sides of the membrane were collected for biochemical analyses and an equivalent volume of 
the fresh medium was added.  
For immunofluoresence microscopy (4.8.5), human AGU fibroblasts were cultured to 
near confluency in a 9.2 cm Petri dish. 2 x106 EBV-transformed AGU lymphocytes were 
added to the culture in 20 ml of RPMI/15% FCS. The cultivation was continued for six days. 
The lymphocytes were washed from the fibroblast culture and the fibroblasts were analyzed 
by immunofluorescence. 
Mannose 6-phosphate inhibition was studied by culturing 1 x106 EBV-transformed 
normal lymphocytes with 4 x106 EBV-transformed AGU lymphocytes in 10 ml of RPMI/FCS 
containing 5 mM mannose 6-phosphate for 10 days. 5 ml of suspension was withdrawn from 
the culture and an equal amount of fresh mannose 6-phosphate-containing media was added 
every second day. 
 
 
4.7 ENZYME REPLACEMENT IN AGU MOUSE MODEL (III, IV) 
 
4.7.1 Preparation of recombinant glycosylasparaginase (III, IV) 
The recombinant human glycosylasparaginase (isoform GA-1) was dialyzed into injection 
buffer containing 150 mM NaCl - 10 mM Tris-HCl, pH 7.5 - 1 mM -glycerophosphate. The 
specific activity of the enzyme preparations were 336 mU/mg of protein (III) or 167 mU/mg 
and 339 mU/mg of protein (IV), determined by fluorometric assay (4.8.1). 
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4.7.2 Treatment of animals (III, IV) 
The animals were handled according to institutional guidelines. The adult AGU mice, from 9 
to 19 months of age, received 1 x 1 mg/kg (0.34 U/kg), 8 x 1 mg/kg (0.34 U/kg) or 8 x 10 
mg/kg (3.4 U/kg) AGA injections into the tail vein in 100 l of injection buffer every second 
day for two weeks (III). One-week-old AGU mice received either 8 x 10 mg/kg (3.4 U/kg) ip 
injections of AGA every second day for two weeks, or 5 x 10 mg/kg (1.7 U/kg) ip/iv injections 
every second day followed by an injection once a week (10 mg/kg; 1.7 U/kg) for 4 weeks (IV). 
Three AGU mice received an intraperitoneal AGA injection (50 mg/kg, 17 U/kg) at the age of 
seven and nine days (IV). For determination of the tissue-half life of the enzyme, the 
heterozygous adult mouse (III) or one-week-old mouse (IV) received a single AGA injection 
of 1 mg/kg (0.34 U/kg). The untreated wild-type (WT) or AGU animals at the same age were 
used as controls. Body weight and general appearance of all the treated animals were 
followed daily (III) or at the time of the injection (IV). 
 
4.7.3 Collection of samples (III, IV) 
Urine samples for determination of the GlcNAc-Asn concentration (4.8.2) were collected on 
filter paper daily (III), or at the time of injection/tissue collection (IV). The blood samples 
were collected to heparinized capillars and plasma was separated for determination of AGA 
activity by fluorometric method (III, 4.8.1). For the biochemical analyses the animals were 
anesthetized and intracardically perfused with 0.9% NaCl (III, IV). The tissues were collected 
and stored at –70oC prior to homogenization and handled in ice after thawing. Tissues were 
homogenized in 50 mM Na-K-phosphate buffer, pH 7.2, containing 0.1% Triton X-100. AGA 
activity from tissue homogenates was determined by HPLC (4.8.1). The AGA activity from 
liver homogenates for determination of tissue half-life of the enzyme was measured by a 
fluorometric method (4.8.1). For electron microscopy (III, 4.9.1) the mice were intracardically 
perfused with 2.5% glutaraldehyde in 0.1 M phosphate buffer, pH 7.4. The tissues were 
removed and stored in 2.5% glutaraldehyde prior to analyses. For immunohistochemical 
studies (4.9.2) the animals were intacardically perfused with 0.9% NaCl, then the tissues 
were removed and immersed in formalin. 
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4.8 BIOCHEMICAL AND OTHER ASSAYS 
 
4.8.1. Assay for glycosylasparaginase activity  
The enzyme activity of the recombinant human glycosylasparaginase (I-IV), the 
glycosylasparaginase activity of cell homogenates from the cell culture experiments (I-II), the 
AGA activity in liver homogenates for tissue half-life (III) and the AGA activity from plasma 
(III) were determined by fluorometric assay using -(7-amido-4-methylcoumarin)-L-aspartic 
acid as a substrate (Mononen et al. 1993b). One unit of the enzyme causes the loss of 1 mol 
of substrate/minute under standard conditions. 
The glycosylasparaginase activity from tissue homogenates was measured by a high-
performance liquid chromatography (HPLC) method as described previously (Kaartinen and 
Mononen 1990a; Kelo et al. 2005). The carboxymethyl cysteine (CmCys) was used as an 
internal standard. The samples were derivatized before they were analyzed on C18 reverse-
phase column. 
 
4.8.2 Aspartylglucosamine assay (I-IV) 
The HPLC method using precolumn derivatization and CmCys as an internal standard were 
used for determination of aspartylglucosamine (GlcNAc-Asn) concentration in the cell (I, II) 
or tissue (III, IV) homogenates (Kaartinen and Mononen 1989; Kaartinen and Mononen 
1990a; Kelo et al. 2005). The GlcNAc-Asn concentrations in urine samples collected on filter 
paper (III, IV) were determined as described previously (Kaartinen and Mononen 1990b). 
 
4.8.3 Protein concentration (I-IV) and creatinine analysis (III, IV) 
Protein concentrations from the purified enzyme preparations, the cell homogenates and the 
tissue homogenates were determined using a Bio-Rad protein assay kit (Bio-Rad 
Laboratories, Richmond, California) according to the manufacturer’s instructions. The 
creatinine analysis from the urine samples was performed in a Konelab 60i clinical chemistry 
analyzer (Thermo Electron Corporation) according to the kinetic Jaffe method. 
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4.8.4. In situ Y-chromosome hybridization assay (II) 
The Onchor Rapid Chromosome In Situ Hybridization kit (Onchor, Inc., Gaithersburg, MD) 
with a fluorescein-labeled Y-chromosome specific DNA-probe was used according to the 
manufacturer’s instructions for identifying the male AGU lymphocytes. 3 times 100 cells 
were counted on the fluorescence microscope to determine the percentage of the Y-
chromosome- containing cells. 
 
4.8.5. Immunofluorescence microscopy (I-II) 
Lymphocytes attached to objective slides or fibroblasts grown in coverslips were fixed with 
methanol and permeabilized with Triton X-100 in PBS. The cells were blocked with FBS or 
FCS and incubated with hen S(156)-R(169) antibodies prepared as described by Kokko and 
Kärenlampi (Kokko and Kärenlampi, 1992). The rabbit anti-hen antibodies were used as a 
secondary antibody, and FITC-conjugated anti-rabbit antibodies were used for detection. The 
preparations were mounted with 50% glycerol in PBS containing 1% n-propylgallate. 
 
 
4.9 HISTOLOGY 
 
4.9.1 Electron microscopy (III) 
The tissues were postfixed with 1% osmium tertoxide, dehydrated and embedded in LX-112 
resin. Ultra-thin sections of the tissues were cut and double-stained with uranyl-asetate and 
lead citrate for transmission electron microscopy (Joel JEM-1200EX, Joel, Chicago, Ill). 
 
4.9.2 Immunohistochemistry (III) 
 
The tissues were postfixed in formalin for 48 hours, after which they were embedded in 
paraffin. 4 m sections were immunostained with a polyclonal hen glycosylasparaginase 
S(156)-R(169) antibody (1:300) or a rabbit immunoserum (1:1000) using the avidin-biotin 
complex method according to the manufacturer’s instructions (Vectastain Elite ABC Kit, 
Vector, Burlingame, California). Polyclonal anti-chicken IgG (Zymed, South San Francisco, 
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California) at a dilution of 1:200 was used as a secondary antibody, and sections were 
counterstained with hematoxylin. 
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5 Results 
 
 
5.1 HUMAN RECOMBINANT OR LEUKOCYTE GLYCOSYLASPARAGINASE AND in vitro 
CORRECTION OF ASPARTYLGLUCOSAMINURIA (I, II) 
 
The human recombinant glycosylasparaginase was purified from the cultured NIH-3T3 
fibroblasts derived from the clone expressing the highest AGA (GA) activity (I). In this cell 
clone, the AGA activity was 120-fold higher than in the non-transfected normal NIH-3T3 
fibroblasts, and the cells did not secrete measurable enzyme activity into the medium during 
the cell culture. In the final purification step of the enzyme by Mono-Q anion exchange 
chromatography, the enzyme eluted in two separate peaks based on charge heterogeneity (I). 
The pooled fractions in the first eluted peak were designated GA-1, and the second eluted 
fractions in a wider peak GA-2. The GA-1 preparation had a higher specific activity than GA-
2 (I). The recombinant AGA consisted of a 24 kDa heavy chain and a 16 kDa light chain with 
a minor portion of a 19 kDa light chain, based on the SDS-PAGE analysis (I). The GA-2 
preparation had a slightly larger portion of the 19 kDa chain than GA-1. Human leukocyte 
AGA eluted in one peak in the last purification step. In this leukocyte enzyme, the light chain 
band appeared at the size of 19 kDa and the minor band at 16 kDa on SDS-PAGE, suggesting 
the difference in the post-translational processing of the light chain of the human 
recombinant and leukocyte AGA. 
The recombinant AGA was taken up by the AGU fibroblasts and lymphocytes (I). The 
endocytosis of GA-2 was more effective than that of GA-1. The normal glycosylasparaginase 
activity (average 20 U/mg; range 17.5-24.5 U/mg, n=8) was reached in EBV-transformed 
AGU lymphocytes within 24 hours from the beginning of the culture when the cell culture 
medium was supplemented of either with 300 mU/l of GA-1 or 10 mU/l of GA-2. The 
endocytosed AGA was localized in the lysosomes of treated cells, according 
immunofluorescence staining of the treated cells. The GlcNAc-Asn storage in AGU 
lymphocytes was on average 5.8 nmol/mg of protein. This storage was cleared under the 
detection limit (less than 0.3 nmol/mg of protein) after the cells were cultured with 1 mU of 
GA-1/l medium for 14 days or with 0.1 mU of GA-2/l medium for 3 days (Table 5). At these 
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time points glycosylasparaginase activity in the cells treated with the GA-1 preparation were 
0.59 U/mg of protein and 0.72 U/mg of protein in the cells treated with the GA-2 
preparation. These activities correspond to approximately 3-4% of the activity in normal 
transformed lymphocytes. 
When the AGU lymphocytes were cultured with AGA purified from human leukocytes, 
the normal AGA activity was reached, and GlcNAc-Asn storage fell below the detection limit 
(0.3 nmol/mg cell protein) in the cells when they were cultured with 300 mU of human 
leukocyte AGA/l of culture medium for one day (II, Table 5). When the culture medium was 
supplemented with 10 mU of AGA/l of culture medium, the GlcNAc-Asn storage was 
cleared on day 7 and further accumulation was prevented in ten-day culture. The activity in 
the cells at that time point was 0.8 U/mg protein, which corresponds to 2-7% of the mean 
activity in the normal lymphocytes (19.4 U/mg; 8.1 -32 U/mg). This effect of treatment is in 
the same range as with recombinant AGA (I). Based on immunofluorescence microscopy, 
leukocyte AGA has been suggested to localize in the lysosomes of the cells, like recombinant 
AGA (II). 
 
Table 5.  AGA activity in AGU lymphocytes during the treatment with recombinant GA-1 or GA-2, or the 
leukocyte AGA on the day when the GlcNAc-Asn concentration in the cells had dropped below the 
detection limit (0.3 nmol/mg cell protein). Bold text indicates the point where the normal AGA 
activity (the average of 20 U/mg of protein) was reached in the cells with various enzyme 
preparations. 
 
 AGA activity in the cell homogenate (U/mg)/Day 
AGA supplementation (mU/ml) GA-1  GA-2 Leukocyte AGA 
0.1 - 0.72 on day 3 - 
1 0.59 on day 14 1.49 on day 2 - 
3 0.15 on day7 4.39 on day1 - 
10 0.6 on day 2 12.3 on day 1 0.8 on day 7 
100 3.2 on day 1 59.5 on day 1 8 on day 1 
300 15.6 on day 1 nd 17.7 on day 1 
 
The half-life of leukocyte enzyme in the cells was approximately one day and 
reaccumulation of the storage was detected four days after the end of the enzyme 
supplementation (1000 U/l for 9 hours) (II). At that time, the AGA activity in the cells had 
fallen below 0.5 U /mg of protein. 
Mannose 6-phosphate was demonstrated to be a competitive inhibitor in the uptake of 
AGA into fibroblasts (I). The inhibition constant Ki was 2 x 10-4 for GA-1 and 6 x 10-4 for GA-
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2. When M6P residues of the enzyme were digested with alkaline phosphatase, or the sugar 
chains were removed by Endoglycosidase H digestion, the transfer of the enzyme was 
completely abolished or at least markedly decreased (Table 6). 
 
Table 6. Effect of alkaline phosphatase (AFOS) or endoglycosidase H (Endo H) treatment on the uptake of 
recombinant glycosylasparaginase (AGA) into AGU fibroblasts. GA-1 and GA-2 preparations were 
studied independently and results are expressed as percentage of untreated GA preparations. 
 
 Enzyme activity after treatment (%) Uptake (%)/mg/h 
Treatment GA-1 GA-2 GA-1 GA-2 
None 100 100 100 100 
AFOS 80 60 11 0 
Endo H 88 84 0 4 
 
 
5.2 CELL-TO-CELL TRANSFER OF GLYCOSYLASPARAGINASE (II) 
 
When the normal and AGU lymphocytes were co-cultured, we found that the normal cells 
grew faster than the AGU cells. However, AGA was transported from the normal to the 
diseased cells in cell-to-cell contact and the transported enzyme was biologically active. The 
lysosomal storage was cleared below the detection limit (0.3 nmol/mg cell protein) when the 
proportion of normal cells was more than 60% in the cell culture containing normal and 
AGU lymphocytes (Table 7).  
 
Table 7. Co-cultivation of normal and AGU lymphocytes. The concentration of normal 
lymphocytes in the cell pool was detected by Y-chromosome in situ 
hybridization (n=1). 
 
Day % of normal cells in cell 
culture on the day stated  
GlcNAc-Asn concentration 
(% of concentration in untreated AGU cells) 
1 80 0 
2 65 0 
8 65 0 
10 60 16 
1-10 0 100 
 
 
In addition, the direct cell-to-cell transport of AGA was not inhibited by adding mannose 6-
phospate into the cell culture medium (Table 8). If the cell-to-cell contact was prevented by a 
semipermeable membrane, no degradation of accumulated storage material was detected in 
the AGU cells (II). 
 
  
44 
Table 8. AGA activity in the cell pool during the co-cultivation of normal 
and AGU lymphocytes with or without addition of mannose-6-
phosphate.  
 
 AGA activity (% of activity in normal lymphocytes) 
Day Without M-6-P (n=1) With M-6-P (n=1) 
0 23 23 
2 39 28 
4 48 46 
6 119 107 
8 90 105 
10 102 105 
 
 
5.3 ENZYME REPLACEMENT THERAPY OF ASPARTYLGLUCOSAMINURIA IN A MOUSE 
MODEL (III, IV) 
 
Intravenously injected AGA was cleared from the systemic circulation of an adult mouse in 
two phases. Within the first phase at half-life of 4 min the enzyme was probably distributed 
into the vascular space or the extracellular fluids, whereas during the second phase at half-
life of 39 min the enzyme was taken up by the tissues (III). 
The main destinations of the AGA enzyme in a mouse body regardless of the age of the 
animal were liver and spleen tissues. The half-life of the enzyme in the liver of adult mice 
was approximately 1.9 days (III) and in newborn mice 1.2 days (IV). After one low-dose (0.34 
U/kg) injection, the AGA activity in the liver of AGU (KO) mice was almost half of that in the 
liver of wild-type (WT) mice (Table 9). When the adult AGU animals had received eight 
injections at this dose, AGA activity comparable to the activity in the tissues of normal 
animals was detected in the liver and spleen (Table 9). When the dose was increased 10-fold 
to 3.4 U/kg, AGA activity in the adult animals increased above the normal activity not only 
in the liver and spleen but also in the heart and jejunum, and was close to normal in the 
kidneys and lung (Table 9). After a two-week therapy with this high enzyme dose (3.4 U/kg) 
in newborn AGU mice, AGA activities were 10-fold higher in the liver and 3-fold higher in 
the spleen than in the tissues of WT animals (Table 9). In the tissues of these animals, the 
kidneys were the only tissue besides the liver and spleen where enzyme activity was 
detected. When the dose was halved to 1.7 U/kg in terms of enzyme activity and the therapy 
was continued for four more weeks with a weekly injection, AGA activity was at the same 
level in the liver and spleen, and double in the kidneys, compared with newborn mice 
treated with a high dose enzyme (3.4 U/kg). Surprisingly, the activity was also detected in 
lung and heart tissues with the lower enzyme dose. 
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The endocytosed exogenous AGA in the tissues of the treated animals degraded the 
accumulated GlcNAc-Asn. The GlcNAc-Asn concentration was cleared from the liver in all 
treated AGU animals of all ages that received eight injections or more (Table 9). When the 
animals were treated with a high enzyme dose (3.4 U/kg), the GlcNAc-Asn concentration fell 
below the detection limit also in spleen, heart, jejunum and kidney tissues in adult animals, 
but not in newborns (Table 9). The spleen was the only tissue besides the liver in newborn 
animals where the GlcNAc-Asn accumulation was terminated by the therapy. The reduction 
of GlcNAc-Asn was more pronounced in the newborn animals treated with the short-term 
high-dose (3.4 U/kg) therapy than in those treated with half the dose for a longer time, even 
though the enzyme activities in the tissues of the animals in this group were higher. In the 
newborn animals, the GlcNAc-Asn concentration decreased more than 80% in all the somatic 
tissues examined in the group of animals treated with the high-dose, compared with a 55-
80% decrease in the other group (Table 9). Interestingly, marked clearance of storage material 
was detected in all tissues in all groups even when no or only a trace amount of enzyme 
activity was detected. The results demonstrate complete clearance of the GlcNAc-Asn in the 
studied tissues of adult mice when AGA activity was above 66% of that in normal tissue. 
This might apply to newborn animals as well. 
The intracellular vacuolization of the tissues of adult AGU animals was seen using 
electron microscopy (III). When these animals were treated with an enzyme injection of 3.4 
U/kg for two weeks, the electron microscopic evaluation showed the clearance of 
intracellular storage vacuoles from the meseangial cells of renal glomeruli, the proximal and 
distal tubules and the collecting tubules of the kidneys, and from the sinusoidal lining cells 
and macrophages of spleen tissue (III). In the liver, which is the most affected organ in AGU, 
the treatment diminished the level of storage material in the storage vacuoles of the 
hepatocytes, the sinusoidal lining cells and the Kupffer cells, but did not completely 
normalize the histological appearance of the tissue (III). In addition, immunohistochemical 
staining of the treated tissues showed extensive and wide staining of the AGA enzyme in the 
sinusoidal lining cells and in the lymphoid cells in the spleen and in the macrophages of red 
pulp in the spleen (III). 
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In addition to somatic tissues, the enzyme was internalized into the brain of the treated 
adult AGU mice. One tenth of the AGA activity in normal adult mice was achieved by eight 
3.4 U/kg injections given every second day (Table 9). This enzyme activity yielded a 21% 
decrease in the GlcNAc-Asn concentration compared with the level of the substrate in 
untreated AGU mice. No enzyme activity was detected in the brains of three-week-old 
AGU mice treated with the same protocol, but a 34% reduction in the storage material was 
detected. Although enzyme activity was detected in the adult brain, it could not be 
localized in any particular cell type or structure by immunohistochemistry. 
In AGU, the large amount of storage material is secreted into urine. The excretion of 
the GlcNAc-Asn into urine during the therapy of adult animals showed that the maximal 
therapeutic effect was achieved within the first 4-5 enzyme injections and the effect was 
sustained at the same level by further injections. The determination of the urinary GlcNAc-
Asn showed dose dependence of the reduction of the excretion (Figure 3). The treatment of 
the adult AGU animals with eight 0.34 U/kg enzyme injections decreased the GlcNAc-Asn 
in urine by 58%. When the enzyme dose was increased 10-fold (8 x 3.4 U/kg), the amount of 
storage was reduced in adult animals by 91% and in newborn animals by 93% compared 
with the urinary concentrations in the untreated adult or newborn mice (Figure 3). After the 
newborn mice had been treated with a lower enzyme dose but for a longer period of time, 
the concentration of GlcNAc-Asn in the urine had decreased approximately to the same 
level as in adult animals treated with a low-enzyme dose (Figure 3). 
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Figure 3. Urinary GlcNAc-Asn of treated AGU mice. The columns represent the 
concentration of GlcNAc-Asn in the urine of adult AGU mice treated with 8 x 0.34 U/kg 
(n=15) (■) and 8 x 3.4 U/kg (n=12)(■), and newborn mice treated with 8 x 3.4 U/kg (n=2) 
(□) or 9 x 1.7 U/kg (n=4) (≡). The bars represent the mean ±range from mean values. 
 
 
5.4 EFFICACY OF EARLY INITATION OF ERT IN AGU (IV) 
 
The GlcNAc-Asn concentration in urine as a proportion of creatinine or in most of the 
somatic tissues as a proportion of protein was higher in newborn animals than in adults. 
However, early initiation of the therapy made no difference to the effect of the therapy on 
lysosomal storage in somatic tissues (Table 9) nor to the overall therapeutic effect, based on 
the urinary excretion of accumulating storage material (Figure 3). In both adult and 
newborn mice, the effect of the therapy with the same treatment protocol was similar. 
The efficacy of the therapy in the brains of newborn animals was more pronounced. 
Although the effect of the therapy was surprisingly high in the adult brain, the GlcNAc-
Asn concentration decreased 14 % more in the brain of newborn animals with the same 
treatment protocol. In addition, when one-week-old AGU mice received two very high 
enzyme injections (17 U/kg) every second day, an 8-17 % increase in AGA activity and a 
41% decrease in the GlcNAc-Asn concentration was detected in the brain tissue 12 hours 
after the second injection (Figure 4). 
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Figure 5. AGA activity (■) and concentration of GlcNAc-Asn (△) in the 9-
day-old mouse brain treated with AGA (17 U/kg) 1, 6 and 12 hours after the 
second injection (n=1). The values at 0 hours represent the AGA activity in the 
brains of untreated WT mice (n=2, ± 1SD) and the concentration of GlcNAc-
Asn in untreated AGU mice (n=2, ± 1SD). 
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6 Discussion 
 
 
Finding a treatment for the lysosomal storage diseases has become a goal of many research 
teams when the pathophysiology of the disease has been discovered. Although the diseases 
in the same subgroup share many common characteristics, they all have disease-specific 
factors that need to be understood and taken into consideration when searching for the 
therapy. When this study was launched, the basic knowledge of the cause of AGU disease 
and the technology to quantitatively measure the compounds of interest were already 
available. Encouraging results related to enzyme replacement therapy in some 
mucopolysacchoridoses and sphingolipidoses channeled the research interest towards ERT 
also in AGU. Finally, the development of DNA techniques provided a tool to produce a 
recombinant protein fundamental to the ERT. In the course of this study the development 
of a mouse model for AGU (Kaartinen et al. 1996; Gonzalez-Gomez et al. 1998) made it 
possible to study the ERT and the enzyme’s efficacy in an animal model. 
When producing recombinant proteins for ERT, a basic but challenging task is to 
achieve the correct post-translational processing of the recombinant enzyme that is crucial 
for its biological activity, for stability and for endocytosis into deficient cells and organs. 
This goal was reached with recombinant glycosylasparaginase in this work. The enzyme 
was biologically active and its properties resembled those of the enzyme purified from 
human leukocytes (Kaartinen et al. 1991). The occurrence of the recombinant AGA in two 
distinguishable peaks in the final purification step, and the difference in the uptake of these 
peaks into the cells, were presumably due to the differences in the post-translational 
processing of polypeptides (e.g. the degree of phosphorylation, position of M6P residues or 
sialylation of the oligosaccharide chains), leading to the slight charge difference between 
these two peaks. However, this processing should not affect the activity of AGA, as seen 
with the glycoasparagines purified from different human or animal sources (Tollersrud and 
Aronson, Jr. 1992). The slightly more charged preparation (GA-2) was more efficiently 
taken up by the cells than the less charged preparation (GA-1), but they both seemed to 
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represent high-uptake forms as the inhibition constants were 10-fold higher than reported 
in the high-uptake hydrolases (Kaplan et al. 1977; Sando and Neufeld 1977; Fischer et al. 
1983). Both of these AGA preparations, like many other lysosomal enzymes, were 
transported into the cells by mannose 6-phosphate receptor-mediated endocytosis. The less 
charged peak, GA-1, was used in in vivo studies due to its higher specific activity. Being less 
charged, it was also hypothesized to be less immunogenic. 
The intravenously injected AGA was cleared from the systemic circulation in two 
phases, like the enzyme in Hurler syndrome (Shull et al. 1994), and the half-life in the 
adults corresponded to the tissue half-lives reported with recombinant N-acetyl-
galactosamine-4-sulfatase in Maroteaux-Lamy syndrome cats (Crawley et al. 1996) and -D-
glucuronidase in MPS VII mice (Vogler et al. 1993). In the cell culture experiments, 
approximately 5% of the normal AGA activity reached in the AGU cells was enough to 
reverse the pathology. Obviously, a mouse and a human are more complicated systems and 
this might not be enough for the whole organism. Indeed, 66% of the normal activity was 
needed in the lung tissue of adult animal to completely clear the GlcNAc-Asn storage. On 
the other hand, a 94% decrease in storage was demonstrated in the lung of 2-week-old mice 
even when no AGA activity was detected. Moreover, a 12% increase in AGA activity in the 
lung of 7-week-old AGU mice led to a 76% decrease in GlcNAc-Asn storage. Despite the 
clearance of the storage in the lysosomes of different tissues, histological changes occur 
more slowly than these biochemical changes. Although the storage was cleared, the empty 
storage vacuoles were still present to a certain extent in many of the tissues studied. This 
emphasizes the fact that therapy should be initiated as early as possible to minimize the 
irreversible changes in tissue pathology prior to the therapy. However, the AGA activities 
in the tissues of the treated adult and newborn AGU mice were not perfectly comparable, 
due to differences in the half-life of the enzyme and to the same timing of the sample 
collection used in the studies. To get comparable results, the samples should probably have 
been collected from the newborn animals sooner after the last injection. These age- related 
differences in the catabolism of the enzyme should have been more carefully addressed 
before the planning of the experiments. 
Resnick et al. have shown that urinary excretion of glycosaminoglycans in different 
mucopolysaccharidoses correlated with cellular levels of this enzyme (Resnick et al. 1992). 
In AGU, a large amount of storage material is secreted into the urine, and this is used to 
  
52 
diagnose the disease. Hence, the urinary level of GlcNAc-Asn could be used as a 
convenient and reliable means for the estimation of the overall therapeutic effect. Indeed, 
GlcNAc-Asn secretion into urine was at the same level with the same treatment protocols 
regardless of the age of the animal, based on the decrease in the GlcNAc-Asn in the urine of 
treated animals compared with untreated mice at the same age, and it also showed clear 
dose dependence. 
The transport of lysosomal enzymes through the adult BBB is controversial. In many 
disorders no enzyme activity, or a decrease in the storage material, have been detected in 
adult brains after ERT (Van der Ploeg et al. 1991; Shull et al. 1994; Crawley et al. 1996), but 
transport has been shown to occur in some disorders such as -mannosidosis, 
metachromatic leukodystrophy and MPS VII (Roces et al. 2004; Matzner et al. 2005; Vogler 
et al. 2005). Interestingly, the 10% increase in AGA activity and 21% decrease in the storage 
in the brain of adult AGU mice are surprisingly high compared with the results of MPS VII 
or MDL. Moreover, AGA was presumably distributed quite diversely into the adult brain, 
since it was not detected by immunohistochemistry. The therapeutic effect in the brain of -
mannosidosis mice was comparable to that of AGU. Both -mannosidosis and 
aspartylglycosaminuria are glycoproteinoses, and the higher therapeutic effect in the brains 
of mice suffering from these diseases might be related to the type of basic metabolic defect. 
On the other hand, Enns and Huhn have suggested that different recombinant enzymes 
might have a different capacity to diffuse into the brain (Enns and Huhn 2008), and Blanz 
and coworkers has proposed an alternative transfer route for a-mannosidase (Blanz et al. 
2008). However, the recombinant AGA used in our study might be one of the enzyme 
preparations that are able to cross the BBB more readily than others. 
In the brains of newborn AGU mice treated with the same protocol and enzyme dose 
as adult animals, and which received a few enzyme injections prior to the full 
developmental maturation of the BBB, an over 30% decrease in lysosomal storage was 
found. The studies done with newborn mice with MPS VII, MPS III or globoid cell 
leukodystrophy have demonstrated similar results (Sands et al. 1994; Gliddon and 
Hopwood 2004; Lee et al. 2005) suggesting the importance of starting the therapy early. The 
changes in the skeleton and in mental function are irreversible and should be prevented by 
starting the therapy early before the symptoms appear. In addition, autophagosytosis 
might be higher in advanced diseases, diminishing the effect of ERT, as shown in mouse 
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Pompe disease (Fukuda et al. 2006). The effect of ERT in the brains of newborn AGU mice 
was marked, but a longer study is needed to determine the effect of the therapy on the 
mental function of the treated mice. Furthermore, to enhance the effect of the therapy in the 
brain, the enzyme should be transported into the brain to an even greater extent. The 
current research in ERT of LSDs has already moved in this direction, and the uptake of 
exogenous enzymes has been improved by adding M6P residues to the enzyme (Zhu et al. 
2004) or by trimming them, for example (Grubb et al. 2008). Moreover, a new approach for 
the targeted delivery of the exogenous enzyme is to link it to a fusion protein domain or 
even the BBB receptor-specific monoclonal antibody, which may then act as an aid in 
penetrating cell membranes (Wadia and Dowdy 2005; Zhang and Pardridge 2005; Cai et al. 
2006; Eavri and Lorberboum-Galski 2007). Finally, growth factors have been used for 
opening the newborn BBB prior to ERT (Young et al. 2004). This step looks promising and 
would be worth exploring in AGU as well. 
The transport of certain lysosomal enzymes from normal lymphocytes into enzyme-
deficient cells has been shown to occur in cell-to-cell contact (Olsen et al. 1981; Olsen et al. 
1983; Abraham et al. 1985). These transported enzymes have been biologically active in 
recipient cells. Enomaa and co-workers showed that GlcNAc-Asn was secreted into cell 
culture medium, from where it was taken up by cells (Enomaa et al. 1995). Different cell 
types might act differently in terms of enzyme secretion. We found that in addition to the 
M6P-mediated uptake of exogenously supplied AGA, the enzyme was transported from 
normal to diseased cells in cell-to-cell contact which did not utilize M6P receptor mediated 
endocytosis. The precise transfer mechanism of this is not clear, but it has been suggested 
that cell-to-cell contact might induce the formation of new lysosomal precursors, which are 
then transported directly into the recipient cells (Abraham et al. 1985; Olsen et al. 1988; 
Bou-Gharios et al. 1993b; Olsen et al.1993). This combined evidence shows that AGA may 
utilize several different transport systems in endocytosis into cells and lysosomes. These 
may play a role in the ERT in terms of breaking the BBB, as in the M6P-independent 
transfer of modified -glucuronidase in the murine brain (Grubb et al. 2008). Furthermore, 
both delivery systems might be utilized in ERT or even in stem cell transplantation, where 
normal stem cells might theoretically differentiate into various cell types depending on the 
microenvironment of the transplant. These cells could then either release corrective enzyme 
into circulation for M6P- dependent uptake or they could correct neighboring cells by 
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contact-mediated transfer of the enzyme. Our study was too short to evaluate the possible 
effect of this contact-mediated correction after ERT. 
The findings related to the treatment of AGU and other lysosomal storage disorders 
give affected patients and their families hope. However, there are also many practical and 
ethical questions to be considered and solved in parallel with scientific research. For 
example, is ERT in its present form suitable for life-long therapy? It is quite cumbersome 
with regular injections, with no common recommendation concerning dosing schedules or 
doses, and with individual-specific differences in the response to the therapy (Kishnani et 
al. 2007). Moreover, it lasts for a lifetime, so the cost of the therapy may become huge. The 
annual cost of treatment of one Gaucher, Fabry, MPS I or MPS VI patient weighing 50 kg 
varies between $145,000 and $377,000 (€112,000-290,000) (Beutler 2006). Therefore, even if 
the recombinant AGA produced in this study proved to be excellent for the therapy, it 
might not be optimal for largescale production in terms of costs of the purification. 
Moreover, what are the costs versus the advantages in terms of the society and the patients, 
and would the therapy be available to every patient who would benefit from it? The high 
costs might even have effects on the social security and health insurance systems in many 
countries in the long run. Health-care systems are not yet ready for expenditure on items 
such as this. Furthermore, what are the opinions of the families and patients towards the 
therapy? Opinions might vary depending on the severity of the disease, which also has to 
be taken into consideration (Coman et al. 2008). However, disease-specific treatment may 
improve the quality of life of the patients dramatically even if not all symptoms are cured 
(Sifuentes et al. 2007). It should be remembered that there is a long way to go from 
preliminary studies to the point where actual treatment can be offered, and that so far ERT 
does not provide a complete cure of any lysosomal disorder. The issues raised above need 
to be considered in relation to AGU as well. 
The milestones in AGU research during the past decade are gathered up in Table 10. 
Moreover, the results described in this study illuminate the disease-specific mechanisms 
related to ERT in AGU in more detail. In addition, these results also contribute to research 
in other glycoproteinosis and lysosomal storage disorders. However, there is still a lot to be 
done in developing a treatment for AGU. For example, the right dose, the timing of the 
injections and the mechanism of enzyme transfer into the brain have to be explored more 
thoughly. Furthermore, ERT should also be followed up for several years to establish its 
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effectiveness in AGU. The long experience of ERT in Gaucher disease has shown this 
therapeutic approach to be safe and efficacous in the therapy of non-neuronal tissues 
(Starzyk et al. 2007), and we might speculate a similar outcome in AGU in terms of safety. 
 
Table 10. Milestones in AGU research from AGU patients’, their families’ and clinicians’ point of view from the time 
this work was initiated to the present day. The data were collected from the references mentioned in Chapter 2 and from 
the publications presented in this thesis. The bold text refers to results of the present study. 
 
 Milestones in research related to AGU AGU patient and family Clinician 
1995 - Screening of the AGUFin mutation is offered to 
pregnant women in Finland. 
- Three-dimensional structure of AGA is generated. 
- Recombinant AGA is generated. 
- M6P-mediated transfer of AGA is detected. 
- In vitro ERT of AGU by recombinant AGA is 
investigated. 
- In vitro gene therapy of AGU is studied. 
- Parents will have to consider ethical 
questions, and knowledge can cause 
distress. 
- Parents may have better choice for 
family planning.  
- Professional skills for meeting 
couples planning a family are 
emphasized.  
- Many ethical questions need to 
be considered also in terms of 
cost of testing. 
- Hope for specific treatment is 
raised. 
1996-
1999 
- AGA is found to be Ntn hydrolase. 
- Activation of AGA is presented. 
- A mouse model for AGU is generated. 
- BMT in human AGU is done. 
- M6P-independent transport of AGA is detected. 
- Murine brain cells are found to internalize AGA by 
M6P. 
- Early initiation of murine BMT is shown to reduce 
vacuolization in the brain. 
- Hopes for treatment are raised.  - A new treatment option 
emerges. 
2000 - ERT in mouse model of AGU is studied. - Hopes for getting a similar therapy as 
in Gaucher disease are raised. 
 
2001 - BMT is not recommended as a treatment if it is 
performed after infancy. 
- M6P-mediated transfer of AGA in cell-to-cell 
contact is demonstrated.  
- Disappointment with BMT as a 
treating option may occur. 
 
- Genetic counseling and carrier 
detection becomes more 
important. 
- Possibility of BMTneeds to be 
estimated as a treatment 
option. 
2003 - Glial cell are shown to be important in gene 
therapy. 
  
2004 - BMT is applied to young AGU mice.   
2006 - Non-viral promoters in gene therapy of murine 
AGU are studied. 
  
2007 - A more precise mechanism of AGA activation is 
presented. 
  
2008 - T2 signal of thalami is detected in AGU patient.   
2009-
2010 
- ERT of young AGU mice is demonstrated to 
be effective in treatment of storage in the 
brain. 
- Frustration with limited therapeutic 
options in spite of hope can occur. 
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7 Conclusions 
 
 
The main aim of the present work was to evaluate the applicability of enzyme replacement 
therapy in aspartylglycosaminuria. This included the production of recombinant 
glycosylasparaginase, and the determination of its efficacy, properties and transfer 
mechanisms in vitro. The efficacy of the recombinant enzyme in correcting the disease in a 
mouse model of AGU was studied. The following goals were achieved: 
 
1. Human recombinant AGA was stably over-expressed and correctly post-translationally 
processed in NIH-3T3 fibroblasts. This recombinant enzyme resembled human 
leukocyte AGA, was unlimited in availability, and efficiently corrected the enzyme 
deficiency and lysosomal storage in AGU lymphocytes and fibroblasts, where it was 
taken up by the mannose 6-phosphate receptor-mediated pathway. 
 
2. Human leukocyte AGA had the same corrective properties as human recombinant 
AGA. The transfer of the AGA enzyme from normal to diseased cells occurred through 
cell-to-cell contact, which did not utilize M6P receptors. Thus human AGA can be 
transferred either with or without M6P-mediated transfer. 
 
3. The recombinant AGA was biologically active in the animal model. The response to the 
therapy was dose-dependent. 10 mg of AGA /kg of animal weight (3.4U/kg) was 
enough to inhibit the substrate accumulation in many somatic tissues including the 
liver and spleen, which were the main targets for the exogenous enzyme. When AGA 
activity was 70% of normal activity in the tissues, the substrate storage fell below the 
detection limit. In addition to the disappearance of storage material, the number of 
storage vacuoles decreased, even though they did not vanish, in many somatic tissues. 
The quantitative analysis of urinary GlcNAc-Asn could be used for the follow-up of the 
treatment effect. The recombinant AGA crossed the adult BBB, and a 10% increase in 
AGA activity and 21% decrease in GlcNAc-Asn storage in brain tissue was detected. 
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4. With the same protocol, the overall therapeutic effect was in the same range in 
newborn animals and in adults. When the therapy was initiated before the full 
development of the BBB, the effect was more marked, with a 30-40% decrease in 
GlcNAc-Asn storage in brain. The results with newborn mice emphasize the 
importance of early initiation of the therapy. 
 
The thesis presents results of the first studies concerning ERT in AGU. The results 
illuminate the disease-specific factors involved in the ERT therapy for AGU, and will form 
a basis for further development of treatment protocols alone or in combination with other 
therapy approaches for this disease. The findings also contribute to research in other LSDs 
with a similar cause. 
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Aspartylglucosaminuria (AGU) is an 
inherited lysosomal storage disease. 
Deficiency of enzyme called glycosy-
lasparaginase results in an accumu-
lation of glycopeptides in cells lead-
ing to a multisystem disease. There 
is no disease-specific treatment for 
AGU. In this study, a treatment ap-
proach called enzyme replacement 
therapy (ERT) was applied to AGU. 
The results reveal disease-specific 
details involved in ERT of AGU and 
form a basis for further development 
of treatment protocols.
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